%PDF-1.3
%
1 0 obj
<<
/Pages 2 0 R
/Type /Catalog
/PageLabels 3 0 R
/Metadata 4 0 R
>>
endobj
5 0 obj
<<
/Producer (QuarkXPress\(tm\) 6.5)
/CreationDate (20070723095507)
/XPressPrivate <2525446F63756D656E7450726F63657373436F6C6F72733A20426C61636B0A2525456E64436F6D6D656E7473>
/Creator (QuarkXPress\(tm\) 6.5)
/ModDate (D:20220412194434+00'00')
>>
endobj
2 0 obj
<<
/Type /Pages
/Kids [6 0 R 7 0 R 8 0 R 9 0 R 10 0 R 11 0 R]
/Count 6
>>
endobj
3 0 obj
<<
/Nums [0 12 0 R]
>>
endobj
4 0 obj
<<
/Type /Metadata
/Subtype /XML
/Length 934
>>
stream
Not for further distribution unless allowed by the License or with the express written permission of Cambridge University Press.
https://doi.org/10.1017/S0317167100006727
https://doi.org/10.1017/S0317167100006727 Published online by Cambridge University Press
2022-04-12T19:44:34+00:00
endstream
endobj
6 0 obj
<<
/Parent 2 0 R
/Type /Page
/MediaBox [0 0 594 783]
/Resources <<
/ProcSet [/PDF /Text]
/Font <<
/F2 13 0 R
/F3 14 0 R
/F0 15 0 R
/F1 16 0 R
/F5 17 0 R
>>
/ExtGState <<
/GS1 18 0 R
/GS2 19 0 R
/GS0 20 0 R
>>
>>
/Contents [21 0 R 22 0 R 23 0 R]
/Annots [24 0 R]
>>
endobj
7 0 obj
<<
/Parent 2 0 R
/Type /Page
/MediaBox [0 0 594 783]
/Resources <<
/XObject <<
/Fm0 25 0 R
>>
/ProcSet [/PDF /Text]
/Font <<
/F0 15 0 R
/F1 16 0 R
/F3 17 0 R
>>
/ExtGState <<
/GS1 18 0 R
/GS2 19 0 R
/GS0 20 0 R
>>
>>
/Contents [26 0 R 27 0 R 28 0 R]
/Annots [29 0 R]
>>
endobj
8 0 obj
<<
/Parent 2 0 R
/Type /Page
/MediaBox [0 0 594 783]
/Resources <<
/XObject <<
/Fm2 30 0 R
/Fm4 31 0 R
>>
/ProcSet [/PDF /Text]
/Font <<
/F3 14 0 R
/F0 15 0 R
/F1 16 0 R
/F4 17 0 R
>>
/ExtGState <<
/GS1 18 0 R
/GS2 19 0 R
/GS0 20 0 R
>>
>>
/Contents [32 0 R 33 0 R 34 0 R]
/Annots [35 0 R]
>>
endobj
9 0 obj
<<
/Parent 2 0 R
/Type /Page
/MediaBox [0 0 594 783]
/Resources <<
/XObject <<
/Fm6 36 0 R
/Fm8 37 0 R
/Fm10 38 0 R
>>
/ProcSet [/PDF /Text]
/Font <<
/F0 15 0 R
/F1 16 0 R
/F3 17 0 R
>>
/ExtGState <<
/GS1 18 0 R
/GS2 19 0 R
/GS0 20 0 R
>>
>>
/Contents [39 0 R 40 0 R 41 0 R]
/Annots [42 0 R]
>>
endobj
10 0 obj
<<
/Parent 2 0 R
/Type /Page
/MediaBox [0 0 594 783]
/Resources <<
/ProcSet [/PDF /Text]
/Font <<
/F3 14 0 R
/F0 15 0 R
/F4 17 0 R
>>
/ExtGState <<
/GS1 18 0 R
/GS2 19 0 R
/GS0 20 0 R
>>
>>
/Contents [43 0 R 44 0 R 45 0 R]
/Annots [46 0 R]
>>
endobj
11 0 obj
<<
/Parent 2 0 R
/Type /Page
/MediaBox [0 0 594 783]
/Resources <<
/ProcSet [/PDF /Text]
/Font <<
/F0 15 0 R
/F1 16 0 R
/F3 17 0 R
>>
/ExtGState <<
/GS1 18 0 R
/GS2 19 0 R
/GS0 20 0 R
>>
>>
/Contents [47 0 R 48 0 R 49 0 R]
/Annots [50 0 R]
>>
endobj
12 0 obj
<<
/S /D
/St 307
>>
endobj
13 0 obj
<<
/Widths [250 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 333 0 0 0
0 0 0 0 0 667 0 0 0 0
0 0 0 0 0 889 0 722 0 0
667 0 0 0 0 0 0 0 0 0
0 0 0 0 0 500 500 444 500 444
333 0 556 278 278 0 278 0 556 500
0 0 0 389 278 556 444 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
444]
/LastChar 142
/FirstChar 32
/Type /Font
/FontDescriptor 51 0 R
/BaseFont /EOZUAU+Times-BoldItalic
/Encoding 52 0 R
/Name /F2
/Subtype /Type1
>>
endobj
14 0 obj
<<
/Widths [250 0 0 0 0 0 0 0 0 0
0 0 250 0 250 0 500 0 500 500
500 0 0 500 0 0 333 0 0 0
0 0 0 611 0 667 722 0 0 0
0 0 444 0 0 833 667 722 0 0
611 500 0 0 611 0 0 0 556 0
0 0 0 0 0 500 500 444 500 444
278 500 500 278 0 444 278 722 500 500
500 500 389 389 278 500 444 0 0 444
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 500]
/LastChar 208
/FirstChar 32
/Type /Font
/FontDescriptor 53 0 R
/BaseFont /YBJVWL+Times-Italic
/Encoding 54 0 R
/Name /F3
/Subtype /Type1
>>
endobj
15 0 obj
<<
/Widths [250 0 0 0 0 833 0 0 333 333
0 564 250 333 250 278 500 500 500 500
500 500 500 500 500 500 278 278 564 564
0 444 0 722 667 667 722 611 556 722
722 333 389 722 611 889 722 722 556 722
667 556 611 722 722 944 0 722 611 0
0 0 0 0 0 444 500 444 500 444
333 500 500 278 278 500 278 778 500 500
500 500 333 389 278 500 500 722 500 500
444 0 0 0 0 0 0 0 0 0
0 0 0 0 444 444 0 0 0 0
444 444 444 0 0 0 0 278 0 0
0 500 0 0 0 0 0 0 0 0
0 0 0 0 0 0 760 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 500 0 0 0
333 333]
/LastChar 213
/FirstChar 32
/Type /Font
/FontDescriptor 55 0 R
/BaseFont /XNBFCG+Times-Roman
/Encoding 56 0 R
/Name /F0
/Subtype /Type1
>>
endobj
16 0 obj
<<
/Widths [250 0 0 0 0 0 0 0 332 332
0 0 0 0 250 0 0 499 499 499
499 499 499 0 0 0 332 0 0 0
0 0 0 721 666 721 721 666 610 776
776 388 0 0 666 942 721 776 0 0
721 555 666 721 0 0 0 0 0 0
0 0 0 0 0 499 555 443 555 443
332 499 0 277 332 555 277 831 555 499
555 555 443 388 332 555 499 0 499 499
0 0 0 0 0 0 0 0 0 666
0 0 0 0 0 0 0 0 0 0
443 443 443]
/LastChar 144
/FirstChar 32
/Type /Font
/FontDescriptor 57 0 R
/BaseFont /CUULHT+Times-Bold
/Encoding 58 0 R
/Name /F1
/Subtype /Type1
>>
endobj
17 0 obj
<<
/Type /Font
/BaseFont /AAAZZD+NotoSans
/Subtype /Type0
/Encoding /Identity-H
/DescendantFonts [59 0 R]
/ToUnicode 60 0 R
>>
endobj
18 0 obj
<<
/OP true
/Type /ExtGState
>>
endobj
19 0 obj
<<
/OP false
/Type /ExtGState
>>
endobj
20 0 obj
<<
/OPM 1
/Type /ExtGState
>>
endobj
21 0 obj
<<
/Filter /FlateDecode
/Length 10
>>
stream
x+ |
endstream
endobj
22 0 obj
<<
/Length 12149
>>
stream
/GS0 gs
1 g
0 783 0 0 re
f
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 52.3994 136.5035 Tm
0 0 0 1 k
0.075 Tw
(Severe closed head injury (CHI) is a significant clinical and)Tj
-1.26316 -1.1579 TD
0.02 Tw
(public health problem, with the Canadian incidence estimated at)Tj
0 -1.15789 TD
0.02 Tc
0.677 Tw
[(1)37(1.4 per 100000.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 120.3259 117.6386 Tm
0 0 0 1 k
(1)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 132.4116 114.5034 Tm
0 0 0 1 k
0.02 Tc
0.677 Tw
(The frequency of use, perceived)Tj
-9.6855 -1.15789 TD
0 Tc
0.04 Tw
(appropriateness, and ef)Tj
9.30669 0.00001 TD
(fectiveness of preventive and therapeutic)Tj
-9.30669 -1.15791 TD
0.003 Tc
0.372 Tw
(interventions for severe CHI remain unknown.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 236.5482 95.6386 Tm
0 0 0 1 k
0.003 Tc
(2,3)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 249.856 92.5034 Tm
0 0 0 1 k
0.003 Tc
(Although)Tj
-22.04806 -1.15789 TD
0.019 Tc
0.356 Tw
(guidelines for the treatment of severe CHI exist,)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 256.1371 84.6386 Tm
0 0 0 1 k
(4)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 265.3313 81.5034 Tm
0 0 0 1 k
0.019 Tc
(some)Tj
-23.67704 -1.15789 TD
0 Tc
0.071 Tw
(investigations have suggested that more aggressive treatment is)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 39.5244 606.3209 Tm
0 0 0 1 k
0.001 Tc
[(ABSTRACT)75(:)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
9.5 0 0 9.5 95.8908 606.3209 Tm
0 0 0 1 k
(Objective: )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 137.6291 606.3209 Tm
0 0 0 1 k
-0.02 Tw
[(T)70(o determine: 1. the degrees of consensus and disagreement among Canadian critical care clinicians regarding)]TJ
-10.32681 -1.1579 TD
0.04 Tw
(the appropriateness (benefit exceeding risk) of common therapeutic manoeuvres in patients with severe closed head injury (CHI), and)Tj
0 -1.15789 TD
-0.013 Tw
(2. the frequency with which clinicians employed these manoeuvres. )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
9.5 0 0 9.5 298.2066 584.3209 Tm
0 0 0 1 k
(Methods:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 337.2225 584.3209 Tm
0 0 0 1 k
-0.013 Tw
(The study design was a systematic scenario-based survey)Tj
-31.33665 -1.15789 TD
0.025 Tw
[(of all neurosur)18(geons and critical care physicians treating patients with severe CHI in Canada. )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
9.5 0 0 9.5 399.037 573.3209 Tm
0 0 0 1 k
(Results:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 435.5244 573.3209 Tm
0 0 0 1 k
0.02 Tc
0.67 Tw
(In the scenario of acute)Tj
-41.68421 -1.15789 TD
0 Tc
0.044 Tw
[(epidural hematoma with mass ef)18(fect, respondents agreed very strongly that sur)17(gery was appropriate. Clinicians reported mannitol and)]TJ
0 -1.1579 TD
0.048 Tw
(hypertonic saline as appropriate. Beyond these two interventions, agreement was less strong, and the use of the extraventricular drain)Tj
0 -1.15789 TD
0.199 Tw
((EVD), phenytoin, cooling, hyperventilation, nimodipine, and jugular venous oximetry (JVO) were of uncertain appropriateness.)Tj
0 -1.1579 TD
0.087 Tw
[(Steroids were considered inappropriate. In a scenario of dif)18(fuse axonal injury (DAI), clinicians agreed strongly that fever reduction,)]TJ
0 -1.15789 TD
0.013 Tw
[(early enteral feeding, intensive glucose control, and cerebral perfusion pressure (CPP)-directed management were appropriate. )18(The use)]TJ
T*
0.202 Tw
[(of mannitol, hypertonic saline, EVD, JVO, narcotics and propofol were also appropriate. Neuromuscular blockade, sur)18(gery)65(, and)]TJ
0 -1.1579 TD
0.083 Tw
[(hyperventilation were of uncertain appropriateness. )18(The appropriateness ratings of the interventions considered in the scenario of an)]TJ
0 -1.15789 TD
0.002 Tw
(intracranial contusion mirrored the DAI scenario. In general, correlations between the reported appropriateness and frequency of use of)Tj
-0.0001 Tc
(each)'
2.07866 0 Td
0 Tc
-0.003 Tw
(intervention were very high. )Tj
11.51201 0 TD
(An exception noted was the use of the JVO. )Tj
17.78314 0 TD
(The correlation between CPP-guided therapy and the use)Tj
-31.37381 -1.1579 TD
0.048 Tw
(of the EVD was weak. )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
9.5 0 0 9.5 129.921 463.3209 Tm
0 0 0 1 k
(Conclusions:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 184.3123 463.3209 Tm
0 0 0 1 k
0.048 Tw
(This survey has described current practice with regard to treatment of patients with severe CHI.)Tj
-15.24083 -1.1579 TD
0.172 Tw
(Areas of variation in perceived appropriateness were identified that may benefit from further evaluation. Suggested priorities for)Tj
0 -1.15789 TD
0.025 Tw
(evaluation include the use of osmotic diuretics, anticonvulsants, and intracranial manometry)Tj
37.06057 0 TD
(.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
8.5 0 0 8.5 39.5244 416.3209 Tm
0 0 0 1 k
0.001 Tc
0.047 Tw
[(R\203SUM\203: )1(Enqu\220te sur)-278(le traitement du traumatisme c\216r\216bral s\216v\217r)18(e au Canada. )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
8.5 0 0 8.5 340.5348 416.3209 Tm
0 0 0 1 k
0.047 Tw
(Objectif :)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
8.5 0 0 8.5 376.2561 416.3209 Tm
0 0 0 1 k
0.047 Tw
(Nous voulions d\216terminer le degr\216 de consensus ou)Tj
-39.6155 -1.29411 TD
0.05 Tw
(de d\216saccord entre les m\216decins r\216animateurs concernant la pertinence (b\216n\216fices/risques) de traitements couramment utilis\216s dans la prise en char)Tj
59.57659 0 TD
0 Tw
(ge)Tj
-59.57659 -1.29412 TD
0.208 Tw
(des traumatismes cr\211niens ferm\216s s\216v\217res (TCF) et la fr\216quence d\325utilisation de ces traitements. )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
8.5 0 0 8.5 390.0799 394.3209 Tm
0 0 0 1 k
0.208 Tw
(M\216thodes : )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
8.5 0 0 8.5 434.6904 394.3209 Tm
0 0 0 1 k
0.208 Tw
[(Nous avons ef)18(fectu\216 une enqu\220te)]TJ
-46.49012 -1.29412 TD
0.02 Tw
[(syst\216matique bas\216e sur des sc\216narios aupr\217s de tous les neurochirur)18(giens et m\216decins r\216animateurs qui traitent des patients atteints de )18(TCF au Canada.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
8.5 0 0 8.5 39.5244 372.3209 Tm
0 0 0 1 k
0.019 Tw
(R\216sultats :)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
8.5 0 0 8.5 79.0323 372.3209 Tm
0 0 0 1 k
0.019 Tw
(Les r\216pondants \216taient fortement d\325accord que la chirur)Tj
22.29457 0 TD
(gie \216tait indiqu\216e chez les patients porteurs d\325un h\216matome \216pidural aigu avec ef)Tj
32.52343 0 TD
0 Tw
(fet)Tj
-59.46599 -1.29413 TD
0.05 Tw
[(de masse. Les m\216decins r\216animateurs consid\216raient que le mannitol et le salin hypertonique \216taient des traitements appropri\216s. )55(Au-del\210 de ces deux)]TJ
0 -1.29412 TD
0.259 Tw
(interventions, le consensus \216tait moins marqu\216, particuli\217rement quant \210 l\325utilisation du drain extraventriculaire (DEV), de la ph\216nyto\225ne, de)Tj
T*
0.224 Tw
[(l\324hypothermie, de l\325hyperventilation, de la nimodipine et de l\325oxym\216trie veineuse par voie jugulaire (OVJ). L)92(\325administration de st\216ro\225des \216tait)]TJ
T*
0.21 Tw
[(consid\216r\216e comme inappropri\216e. En ce qui concerne le traumatisme axonal dif)18(fus \(T)79(AD\), les m\216decins r\216animateurs consid\216raient comme tr\217s)]TJ
T*
-0.026 Tw
(appropri\216s une diminution de la fi\217vre, une alimentation ent\216rale pr\216coce, un contr\231le glyc\216mique serr\216 et le r\216tablissement ou le maintien de la pression)Tj
T*
0.063 Tw
(de perfusion c\216r\216brale. L)Tj
10.40275 0.00001 TD
(\325utilisation du mannitol, du salin hypertonique, du DEV)Tj
22.66753 0 TD
-0.0001 Tc
(,)Tj
0.56262 0 Td
0 Tc
(de l\325OVJ, des narcotiques et du propofol \216taient aussi consid\216r\216es)Tj
-33.6329 -1.29413 TD
0.1 Tw
(comme appropri\216es. La pertinence de l\325utilisation de substances myor\216solutives, de la chirur)Tj
38.09605 0 TD
(gie et de l\325hyperventilation \216taient consid\216r\216es comme)Tj
-38.09605 -1.29412 TD
0.08 Tw
[(incertaines. Les taux de pertinence des interventions envisag\216es dans le sc\216nario d\325une contusion intracr\211nienne refl\216taient le sc\216nario du )18(T)80(AD. En)]TJ
T*
0.215 Tw
(g\216n\216ral, les corr\216lations entre la pertinence rapport\216e et la fr\216quence d\325utilisation de chaque intervention \216taient tr\217s \216lev\216es, \210 l\325exception de)Tj
0 -1.29411 TD
0.03 Tw
[(l\325utilisation de l\325OVJ. La corr\216lation entre le traitement guid\216 par la pression de perfusion c\216r\216brale et l\325utilisation du DEV)-263(\216tait faible. )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
8.5 0 0 8.5 510.4958 262.3209 Tm
0 0 0 1 k
(Conclusions)Tj
-55.4084 -1.29412 TD
-0.0002 Tc
(:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
8.5 0 0 8.5 44.459 251.3209 Tm
0 0 0 1 k
-0.002 Tw
[(Cette enqu\220te d\216crit les pratiques en vigueur dans le traitement des patients pr\216sentant un )18(TCF)79(. Nous avons identifi\216 des variations dans la perception)]TJ
-0.58054 -1.29412 TD
0.012 Tw
(de la pertinence de certains traitements qui pourraient faire l\325objet d\325une \216valuation plus pouss\216e. Nous sugg\216rons les priorit\216s d\325\216valuation suivantes:)Tj
T*
0.025 Tw
(l\325utilisation de diur\216tiques osmotiques, d\325anticonvulsivants et de la manom\216trie intracr\211nienne.)Tj
ET
1 w
0 0 0 1 K
39.524 175.821 m
553.948 175.821 l
S
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 405.8225 194.3209 Tm
0 0 0 1 k
0.025 Tw
(Can. J. Neurol. Sci. 2007; 34: 307-312)Tj
ET
0 0 0 0 k
39.297 27.493 516.875 38.507 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9 0 0 9 39.2971 29.4446 Tm
0 0 0 1 k
-0.0001 Tc
(THE)Tj
2.21865 0 Td
0 Tc
0.025 Tw
[(CANADIAN JOURNAL)-238(OF NEUROLOGICAL)-238(SCIENCES)-28963(307)]TJ
ET
4 w
0 0 0 1 K
159.431 749.494 m
554.806 749.494 l
S
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
22 0 0 22 159.4306 719.4942 Tm
0 0 0 1 k
0.001 Tc
0.025 Tw
[(Survey of Management of Sever)19(e Head)]TJ
0 -1.18182 TD
[(Injur)1(y in Canada )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
12 0 0 12 159.4306 663.4942 Tm
0 0 0 1 k
0.025 Tw
(Michael J. Jacka, David Zygun, )Tj
ET
1 w
0 0 0 1 K
39.431 628.994 m
554.806 628.994 l
S
BT
/F3 1 Tf
12 0 0 12 159.4306 647.4942 Tm
[(On behalf of the Canadian Neur)37(ocritical Car)37(e Society )]TJ
ET
0 0 0 0 k
307.8 70.3 247.176 74.193 re
f
307.8 130.3179 m
554.976 130.3179 l
S
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
7 0 0 7 307.8 111.8176 Tm
0 0 0 1 k
0.025 Tw
[(From the Department of )55(Anesthesiology)65(, Division of Critical Care (MJJ), University of)]TJ
0 -1.14286 TD
(Alberta, Edmonton; Departments of Critical Care Medicine, Clinical Neurosciences)Tj
0 -1.14285 TD
[(and Community Health Sciences (DZ), University of Calgary)65(, Calgary)65(, )55(AB, Canada.)]TJ
1.71429 -1.14286 TD
(R)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
5.25 0 0 5.25 324.4689 87.8176 Tm
0 0 0 1 k
(ECEIVED)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
7 0 0 7 348.8436 87.8176 Tm
0 0 0 1 k
(O)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
5.25 0 0 5.25 353.8971 87.8176 Tm
0 0 0 1 k
(CT)Tj
1.26 0.00001 TD
(OBER)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
7 0 0 7 376.4376 87.8176 Tm
0 0 0 1 k
0.025 Tw
(13, 2006. )Tj
3.99508 0.00001 TD
(A)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
5.25 0 0 5.25 409.4566 87.8176 Tm
0 0 0 1 k
(CCEPTED)Tj
4.81099 0.00001 TD
(IN)Tj
1.42138 0.00001 TD
(FINAL)Tj
3.27316 0.00001 TD
(FORM)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
7 0 0 7 476.1627 87.8176 Tm
0 0 0 1 k
(M)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
5.25 0 0 5.25 482.3851 87.8176 Tm
0 0 0 1 k
(ARCH)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
7 0 0 7 498.8938 87.8176 Tm
0 0 0 1 k
0.025 Tw
(10, 2007.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
7 0 0 7 307.8 79.8176 Tm
0 0 0 1 k
0.025 Tw
[(Reprint r)37(equests to:)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
7 0 0 7 365.412 79.8176 Tm
0 0 0 1 k
0.025 Tw
[(Michael J. Jacka, GSICU, )18(WCM HSC, University of )55(Alberta, 8440)]TJ
-8.23029 -1.14285 TD
-0.0001 Tc
(-)Tj
0.60776 0 Td
(1)Tj
0.46314 0.00001 TD
0 Tc
[(12 Street NW)92(, Edmonton, )55(Alberta, )17(T6G 2B7, Canada.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9 0 0 9 39.4306 741.3389 Tm
0 0 0 1 k
0.0013 Tc
(O)Tj
0.77732 0.00001 TD
0.001 Tc
[(RIGINAL)-164(A)-1(R)36(TICLE)]TJ
ET
0.5 w
0 0 0 1 K
159.3038 751.2395 m
39.3998 751.2395 l
S
/GS2 gs
Q
endstream
endobj
23 0 obj
<<
/Filter /FlateDecode
/Length 238
>>
stream
xmMK@_mo(X$zIwIT-VkA;0;,<ۊe'Nzٽ1R'
LUjc%UamP.B:xt4P*M%-Jo'7q-OpsF=1x 瘑R1'{VSjʳHt>ź#d
hc
(Ykh1nC6iH9)F+
^Y|kӪ!n~r7|
endstream
endobj
24 0 obj
<<
/Type /Annot
/Subtype /Link
/Rect [7.7999997 14.264648 133.62 22.189453]
/Border [0 0 0]
/A 61 0 R
>>
endobj
25 0 obj
<<
/Name /Fm0
/BBox [0 0 593.99994 782.99994]
/Subtype /Form
/Resources <<
/XObject <<
/Fm1 62 0 R
>>
/ProcSet [/PDF]
/ExtGState <<
/GS3 63 0 R
>>
>>
/Type /XObject
/Length 63
/Matrix [1 0 0 1 0 0]
/OPI <<
/1.3 <<
/ImageType [1 1]
/Resolution [300 300]
/Version 1.3
/Size [1911 1949]
/CropRect [40 27 1870 1925]
/CropFixed [39.692 27.487 1870.05603 1925.00598]
/Overprint false
/Type /OPI
/F (Production-HD:Users:Production:Production Documents:Production Documents: Journal in Progress: 34#3 Aug 2007:figures tables:3128 table 1.tif)
/ColorType /Process
/Position [307.79999 70.882 307.79999 325.90799 553.79999 325.90799 553.79999 70.882]
/Color [0 0 0 1 (Black)]
>>
>>
/FormType 1
>>
stream
/GS3 gs
q
246.48851 0 0 255.49332 307.573 70.6136 cm
/Fm1 Do
Q
endstream
endobj
26 0 obj
<<
/Filter /FlateDecode
/Length 10
>>
stream
x+ |
endstream
endobj
27 0 obj
<<
/Length 8909
>>
stream
/GS0 gs
1 g
0 783 0 0 re
f
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 40.024 716.0964 Tm
0 0 0 1 k
0.077 Tw
(associated with better outcomes.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 165.684 719.2314 Tm
0 0 0 1 k
(5)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 171.761 716.0964 Tm
0 0 0 1 k
0.077 Tw
[(V)111(ariation among clinicians in)]TJ
-13.86705 -1.15789 TD
0.024 Tw
(treatment of severe CHI may derive from uncertainty associated)Tj
T*
0.004 Tc
0.371 Tw
(with the relative weakness of the supporting evidence.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 272.9246 697.2315 Tm
0 0 0 1 k
0.004 Tc
(3,4,6)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 40.024 683.0964 Tm
0 0 0 1 k
0.298 Tw
[(Consequently)65(, a substantial portion of clinical practice with)]TJ
0 -1.15789 TD
0.052 Tw
(severe CHI may be supported by consensus on \324usual practice\325,)Tj
T*
0.025 Tw
(either by clinician or institution, leading to practice variation.)Tj
1.26316 -1.57895 TD
(The purpose of this investigation was to determine:)Tj
0 -1.1579 TD
(1. the degree of consensus among Canadian clinicians )Tj
0 -1.15789 TD
-0.022 Tw
(regarding the appropriate management of patients with severe)Tj
T*
0 Tw
(CHI )Tj
0 -1.1579 TD
0.025 Tw
(2. the frequency with which clinicians employed common )Tj
0 -1.15789 TD
(therapeutic manoeuvres)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 40.024 569.0964 Tm
0 0 0 1 k
(M)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.125 0 0 7.125 48.9906 569.0964 Tm
0 0 0 1 k
0.0015 Tc
(E)Tj
0.6675 -0.00001 TD
0.001 Tc
(THODS)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 52.024 554.0964 Tm
0 0 0 1 k
0.285 Tw
[(The sampling frame was a census of neurosur)18(geons and)]TJ
-1.26316 -1.15789 TD
0.274 Tw
(critical care physicians treating patients with severe CHI in)Tj
0 -1.1579 TD
0.368 Tw
[(Canada. )18(The study design was a systematic survey of all)]TJ
0 -1.15789 TD
0.107 Tw
[(physicians in the census. )55(Approval for this study was obtained)]TJ
0 -1.1579 TD
0.301 Tw
[(from the University of )55(Alberta Health Research and Ethics)]TJ
T*
0.261 Tw
[(Board. Since this was a self-completed survey)65(, consent was)]TJ
0 -1.15789 TD
0.237 Tw
[(implied by survey response. )18(The voluntary nature and study)]TJ
0 -1.1579 TD
0.025 Tw
[(purpose were described in the survey cover letter)55(.)]TJ
1.26316 -1.1579 TD
0.112 Tw
(The Canadian Hospitals Directory was reviewed to identify)Tj
-1.26316 -1.15789 TD
0.071 Tw
(all Canadian hospitals. )Tj
9.52561 0 TD
(The administration of each hospital was)Tj
-9.52561 -1.1579 TD
0.163 Tw
(contacted by telephone to verify whether patients with severe)Tj
0 -1.15789 TD
0.2 Tw
(CHI were admitted and treated, or generally transferred. )Tj
24.2912 0 TD
0 Tw
(The)Tj
-24.2912 -1.1579 TD
-0.014 Tw
(heads of the hospital intensive care unit (ICU) and department of)Tj
T*
0.148 Tw
[(neurosur)18(gery (NS) were also identified. In all hospitals where)]TJ
0 -1.15789 TD
-0.006 Tw
(patients with severe CHI were admitted and treated, the ICU and)Tj
0 -1.1579 TD
(NS heads were contacted by telephone or electronic mail (email))Tj
T*
-0.002 Tw
[(to identify all critical care physicians and neurosur)18(geons directly)]TJ
0 -1.15789 TD
0.064 Tw
[(involved in treating patients with severe CHI. )18(These physicians)]TJ
0 -1.1579 TD
0.025 Tw
[(became the sampling frame of the study)65(.)]TJ
1.26316 -1.1579 TD
0.053 Tw
(Item generation for the survey consisted of a comprehensive)Tj
-1.26316 -1.15789 TD
0.322 Tw
(Medline search of all articles published between 1966 and)Tj
0 -1.1579 TD
-0.033 Tw
(November 2004. Item reduction was performed by a panel of ten)Tj
T*
0.062 Tw
(experts in head injury management, including five experts each)Tj
0 -1.15789 TD
0.093 Tw
(in ICU and NS, in order to eliminate bizarre items \(e.g. herbal)Tj
T*
0.095 Tw
[(therapy\) and those of historical interest only)65(, and to ensure the)]TJ
0 -1.1579 TD
0.148 Tw
[(otherwise comprehensive nature of the items. )18(The survey was)]TJ
0 -1.15789 TD
0.32 Tw
(based on scenarios that were intended to suggest an acute)Tj
T*
0.236 Tw
(traumatic epidural hematoma (EPI), dif)Tj
16.66878 0.00001 TD
(fuse small vessel and)Tj
-16.66878 -1.15791 TD
0 Tw
(subarachnoid hemorrhage (DAI), and intracranial contusion (IC))Tj
0 -1.15789 TD
0.153 Tw
[((Appendix I). )18(The survey was pilot-tested and retested on the)]TJ
T*
0.294 Tw
(group of experts, and the kappa correlation coef)Tj
21.19373 0.00001 TD
(ficient was)Tj
-21.19373 -1.15791 TD
0.009 Tw
(calculated for each response. Responses with a test-retest kappa)Tj
0 -1.15789 TD
0.025 Tw
(of 0.75 or less were removed. )Tj
1.26316 -1.15789 TD
0.003 Tc
0.372 Tw
(The final survey was mailed to each physician of the)Tj
-1.26316 -1.1579 TD
0 Tc
-0.035 Tw
[(sampling frame on January 30, 2005. )18(The survey was announced)]TJ
0 -1.15789 TD
0.091 Tw
(to the head of ICU and NS at each site by fax and email, with)Tj
T*
0.114 Tw
(suggestions to encourage response. Non-responders to the first)Tj
0 -1.1579 TD
0.033 Tw
(mailing were sent a follow-up letter and survey on February 28,)Tj
0 -1.15789 TD
0.095 Tw
[(2005. )55(A)-290(third mailing was sent to persistent non-responders on)]TJ
T*
0.147 Tw
(March 30, 2005. Contact with non-responders to the first two)Tj
0 -1.1579 TD
0.211 Tw
[(mailings was attempted by telephone and email during )55(April)]TJ
0 -1.15789 TD
0.025 Tw
(2005. )Tj
1.26316 -1.15789 TD
0.115 Tw
(Survey responses were tabulated and analysed using SAS\250)Tj
-1.26316 -1.1579 TD
0.124 Tw
[(\(Cary)65(, NC\). Descriptive and analytic statistics were employed,)]TJ
0 -1.15789 TD
0.222 Tw
(using parametric and non-parametric methods as appropriate.)Tj
28.33011 68.0975 TD
0.007 Tw
(The Bonferroni correction for multiple comparisons was applied)Tj
0 -1.15789 TD
0.025 Tw
(as appropriate.)Tj
1.26316 -1.15789 TD
0.289 Tw
(Survey responses were analysed by a priori grouping of)Tj
-1.26316 -1.1579 TD
0.039 Tw
(appropriateness and frequency scores into three main categories)Tj
0 -1.15789 TD
0.041 Tw
[(in order to facilitate the summary)65(. )55(Appropriateness scores were)]TJ
T*
-0.011 Tw
(reported as raw scores, and then grouped for each intervention to)Tj
0 -1.1579 TD
0.111 Tw
(describe them as appropriate \(5.0 to 7.0\), inappropriate \(1.0 to)Tj
0 -1.15789 TD
0.002 Tc
0.373 Tw
[(2.9\), and uncertain appropriateness \(3.0 to 4.9\). Similarly)65(,)]TJ
T*
0 Tc
0.195 Tw
(frequency scores were reported as raw scores, and were also)Tj
0 -1.1579 TD
0.074 Tw
(grouped as frequent/always (3.7 to 5.0), rare/never (1.0 to 2.3),)Tj
0 -1.15789 TD
0.024 Tw
[(and occasional (2.4 to 3.6). )18(The frequency scores were inverted)]TJ
T*
0.017 Tc
0.358 Tw
(between the survey and the report in order to facilitate)Tj
0 -1.1579 TD
0 Tc
0.025 Tw
(interpretation (e.g. 1 became 5, 2 became 4, etc.).)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 309.16 563.0228 Tm
0 0 0 1 k
(R)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.125 0 0 7.125 316.0183 563.0228 Tm
0 0 0 1 k
0.001 Tc
[(ESUL)93(T)-1(S)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 321.16 548.0228 Tm
0 0 0 1 k
-0.014 Tw
(Thirty-one hospitals in Canada were identified where patients)Tj
-1.26316 -1.1579 TD
0.06 Tw
[(with severe CHI were admitted and treated. )55(At these sites, 247)]TJ
0 -1.15789 TD
0.236 Tw
(physicians, including 99 neurosur)Tj
14.1863 0.00001 TD
(geons and 148 critical care)Tj
-14.1863 -1.1579 TD
0.005 Tc
0.37 Tw
(physicians, were identified as attending on these patients.)Tj
T*
0 Tc
0.03 Tw
(Responses were received from 29 of the 31 sites surveyed \(both)Tj
0 -1.15789 TD
0.108 Tw
(of the non-responding sites were in Quebec\). Responses were)Tj
0 -1.1579 TD
0.28 Tw
(received from 59 NS and 82 ICU physicians, totalling 141)Tj
0 -1.15789 TD
0.025 Tw
(responses (57% overall response rate). )Tj
1.26316 -1.1579 TD
0.135 Tw
(Considering the demographic characteristics of respondents)Tj
-1.26316 -1.1579 TD
0.131 Tw
[(\(T)69(able 1\), the majority of respondents were male \(90.8%\) and)]TJ
0 -1.15789 TD
0.008 Tw
(younger than age 40 (43.9%). Respondents had been in practice)Tj
0 -1.1579 TD
0.043 Tw
(for an average of 1)Tj
7.68439 0 TD
(1.9 years. Most ICUs were \324closed\325)Tj
14.9132 0 TD
0 Tw
((57.3%))Tj
-22.59759 -1.1579 TD
0.15 Tw
(and included an average of 19 beds, which were occupied by)Tj
ET
0 0 0 0 k
39.696 726 516 30 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9 0 0 9 39.696 749.8455 Tm
0 0 0 1 k
-0.0001 Tc
(THE)Tj
2.21865 0 Td
0 Tc
0.025 Tw
[(CANADIAN JOURNAL)-238(OF NEUROLOGICAL)-238(SCIENCES)]TJ
-2.21865 -80.04603 TD
(308)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 308.8 345.8102 Tm
0 0 0 1 k
(T)Tj
0.5752 0 TD
0.001 Tc
0.025 Tw
(able 1: Descriptors of Response Gr)Tj
14.9629 0.00001 TD
0 Tw
(oup)Tj
ET
1 w
0 0 0 1 K
307.8 70.713 m
554.976 70.713 l
S
307.8 359.371 m
554.976 359.371 l
S
0.5 w
307.8 326.371 m
554.976 326.371 l
S
/GS2 gs
q
307.8 70.882 246 255.026 re
W n
/Fm0 Do
Q
Q
endstream
endobj
28 0 obj
<<
/Filter /FlateDecode
/Length 238
>>
stream
xmK0[n*8rdI&ulvLnu^Z /{bJ/ӻX_q_/pZim>VR+.c,| Dcw#O*T V8Ux]t62[lxBk3j9nj4sgu99<.0Sy-ǠVyC>,^Ǝ=64hNqz8
(r+~mZ
77x
endstream
endobj
29 0 obj
<<
/Type /Annot
/Subtype /Link
/Rect [7.7999997 14.264648 133.62 22.189453]
/Border [0 0 0]
/A 64 0 R
>>
endobj
30 0 obj
<<
/Name /Fm2
/BBox [0 0 593.99994 782.99994]
/Subtype /Form
/Resources <<
/XObject <<
/Fm3 65 0 R
>>
/ProcSet [/PDF]
/ExtGState <<
/GS3 63 0 R
>>
>>
/Type /XObject
/Length 61
/Matrix [1 0 0 1 0 0]
/OPI <<
/1.3 <<
/ImageType [1 1]
/Resolution [300 300]
/Version 1.3
/Size [1876 1060]
/CropRect [38 27 1784 1029]
/CropFixed [38.356 26.585 1784.11902 1028.76501]
/Overprint false
/Type /OPI
/F (Production-HD:Users:Production:Production Documents:Production Documents: Journal in Progress: 34#3 Aug 2007:figures tables:3128 table 2.tif)
/ColorType /Process
/Position [39.024 546.526 39.024 688.42102 286.20001 688.42102 286.20001 546.526]
/Color [0 0 0 1 (Black)]
>>
>>
/FormType 1
>>
stream
/GS3 gs
q
247.6344 0 0 142.2942 38.832 546.3508 cm
/Fm3 Do
Q
endstream
endobj
31 0 obj
<<
/Name /Fm4
/BBox [0 0 593.99994 782.99994]
/Subtype /Form
/Resources <<
/XObject <<
/Fm5 66 0 R
>>
/ProcSet [/PDF]
/ExtGState <<
/GS3 63 0 R
>>
>>
/Type /XObject
/Length 60
/Matrix [1 0 0 1 0 0]
/OPI <<
/1.3 <<
/ImageType [1 1]
/Resolution [300 300]
/Version 1.3
/Size [1872 812]
/CropRect [35 21 1781 791]
/CropFixed [35.314 21.188 1781.078 790.703]
/Overprint false
/Type /OPI
/F (Production-HD:Users:Production:Production Documents:Production Documents: Journal in Progress: 34#3 Aug 2007:figures tables:3128 table 3.tif)
/ColorType /Process
/Position [39.024 71.648 39.024 180.601 286.20001 180.601 286.20001 71.648]
/Color [0 0 0 1 (Black)]
>>
>>
/FormType 1
>>
stream
/GS3 gs
q
247.6344 0 0 109.3046 38.838 71.4643 cm
/Fm5 Do
Q
endstream
endobj
32 0 obj
<<
/Filter /FlateDecode
/Length 10
>>
stream
x+ |
endstream
endobj
33 0 obj
<<
/Length 8322
>>
stream
/GS0 gs
1 g
0 783 0 0 re
f
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 40.024 481.5035 Tm
0 0 0 1 k
0.089 Tw
[(\324adults only\325)-265(in most cases (75.2%). )17(The average hospital was)]TJ
0 -1.15789 TD
0.004 Tw
(between 400 and 750 beds (55.5%) and located in a city of more)Tj
0 -1.1579 TD
0.194 Tw
(than 500000 (50%). Respondents estimated the incidence of)Tj
T*
0.07 Tw
(head injury to be stable or decreasing (82.4%), with a stable or)Tj
0 -1.15789 TD
0.025 Tw
(increasing survival (57.5%).)Tj
1.26316 -1.1579 TD
0.008 Tc
0.366 Tw
(Appropriateness data are summarized by their a priori)Tj
-1.26316 -1.1579 TD
0 Tc
0.337 Tw
[(groupings according to scenario in )18(T)70(able 2 as appropriate,)]TJ
0 -1.15789 TD
-0.005 Tw
(uncertain appropriateness, and inappropriate. Frequency data are)Tj
0 -1.1579 TD
0.201 Tw
[(similarly summarized in )18(T)70(able 3 as frequent, occasional, and)]TJ
T*
0.025 Tw
(infrequent. )Tj
1.26316 -1.15789 TD
0 Tw
(From )Tj
2.76474 0 TD
(T)Tj
0.54101 0 TD
0.366 Tw
(able 2, clinicians agreed very strongly that EPI)Tj
-4.56891 -1.1579 TD
0.057 Tw
(required sur)Tj
4.84204 0 TD
(gery \(6.9 \(range 6.7 \320 7.0\)\). \(Data are described as)Tj
-4.84204 -1.1579 TD
0.368 Tw
(means \(+/- standard deviation\) unless otherwise indicated.\))Tj
0 -1.15789 TD
0.097 Tw
(Clinicians reported mannitol as appropriate for EPI (5.6 (1.3)),)Tj
0 -1.1579 TD
0.132 Tw
(and appeared to consider hypertonic saline as appropriate \(4.9)Tj
T*
0.064 Tw
(\(1.7\)\). Beyond these two interventions for EPI, agreement was)Tj
0 -1.15789 TD
0.216 Tw
(less strong, and the use of the extraventricular drain (EVD),)Tj
0 -1.1579 TD
0.242 Tw
(phenytoin, cooling, hyperventilation, nimodipine, and jugular)Tj
T*
0.003 Tc
0.372 Tw
(venous oximetry (JVO) were of uncertain appropriateness.)Tj
0 -1.15789 TD
0 Tc
0.025 Tw
(Steroids (2.6 (1.1)) were considered to be inappropriate for EPI.)Tj
29.59327 46.7915 TD
0.001 Tc
0.374 Tw
[(When DAI was considered \(T)70(able 2\), clinicians agreed)]TJ
-1.26316 -1.15789 TD
0 Tc
0.18 Tw
(strongly that fever reduction (6.3 (0.8)), early enteral feeding)Tj
T*
0.191 Tw
((6.1 (1.0)), intensive glucose control (6.1 (0.9)), and cerebral)Tj
0 -1.1579 TD
0.06 Tw
(perfusion pressure (CPP)-directed management (6.0 (0.9)) were)Tj
0 -1.15789 TD
0.094 Tw
[(appropriate. )18(The use of mannitol (5.6 (1.0)), hypertonic saline)]TJ
T*
0.126 Tw
((5.4 (1.1)), the EVD (5.3 (1.4)), and the JVO (5.3 (1.3)) were)Tj
0 -1.1579 TD
0.189 Tw
(also appropriate, as were the use of narcotics (5.3 (1.4)) and)Tj
0 -1.15789 TD
0.269 Tw
(propofol sedation \(5.4 \(1.1\)\). Neuromuscular blockade \(4.7)Tj
T*
0.064 Tw
[(\(1.4\)\), sur)18(gery (3.6 (1.7)), and hyperventilation (3.7 (1.7)) were)]TJ
0 -1.1579 TD
0.062 Tw
(of uncertain appropriateness. No intervention was described as)Tj
0 -1.15789 TD
0 Tw
(inappropriate.)Tj
1.26316 -1.15789 TD
0.154 Tw
(The appropriateness ratings of the interventions considered)Tj
-1.26316 -1.1579 TD
0.055 Tw
(for treatment of IC were very similar in direction and degree to)Tj
0 -1.15789 TD
0.025 Tw
[(DAI \(T)70(able 2\).)]TJ
1.26316 -1.15789 TD
0.043 Tw
(Comparing the reported appropriateness of each intervention)Tj
-1.26316 -1.1579 TD
0.009 Tc
0.366 Tw
[(by neurosur)18(geons and intensive care physicians \(data not)]TJ
0 -1.15789 TD
0 Tc
0.093 Tw
[(shown\), neurosur)18(geons were significantly more likely to report)]TJ
T*
0.207 Tw
[(the use of sur)18(gery and mannitol as appropriate for EPI \(p =)]TJ
0 -1.1579 TD
0.007 Tc
0.368 Tw
(0.0001 for both\), although both groups agreed that these)Tj
0 -1.15789 TD
0 Tc
0.025 Tw
(interventions were appropriate. In the treatment of DAI and IC,)Tj
T*
0.183 Tw
(both groups were similar in reported appropriateness of most)Tj
0 -1.1579 TD
0.187 Tw
(interventions. However)Tj
9.96999 0 TD
-0.0001 Tc
(,)Tj
0.68722 0 Td
0 Tc
(ICU physicians reported using early)Tj
-10.65721 -1.1579 TD
0.182 Tw
(enteral feeding and intensive glucose control more frequently)Tj
T*
0.025 Tw
[(than neurosur)18(geons for both DAI and IC (p < 0.001).)]TJ
1.26316 -1.15789 TD
-0.037 Tw
(Considering the reported frequency of use of the interventions)Tj
-1.26316 -1.1579 TD
0.158 Tw
[(in EPI \(T)70(able 3\), sur)17(gery and mannitol were reported as very)]TJ
T*
0.02 Tc
0.508 Tw
(frequently used (4.7 (0.6) and 3.8 (0.9) respectively).)Tj
0 -1.15789 TD
0 Tc
0.206 Tw
(Interventions that were used occasionally in selected patients)Tj
0 -1.1579 TD
0.102 Tw
(included phenytoin (3.2 (1.4)), hyperventilation (3.0 (1.0)), the)Tj
T*
0.027 Tw
(EVD \(2.9 \(1.1\)\), and cooling \(2.9 \(1.1\)\). Hypertonic saline \(2.2)Tj
0 -1.15789 TD
0.046 Tw
(\(1.1\)\), steroids \(1.2 \(0.5\)\), nimodipine \(1.2 \(0.6\)\), and JVO \(1.6)Tj
0 -1.1579 TD
0.025 Tw
(\(0.7\)\) were reported as rarely if ever used. )Tj
1.26316 -1.1579 TD
0.009 Tc
0.366 Tw
(The reported frequency of use of interventions among)Tj
-1.26316 -1.15789 TD
0 Tc
0.156 Tw
(patients with DAI and IC were similar \(T)Tj
17.54617 0 TD
(able 3\). Frequently)Tj
-17.54617 -1.1579 TD
0.02 Tc
0.455 Tw
(used interventions included early enteral feeding, fever)Tj
T*
0 Tc
0.185 Tw
[(reduction, intensive glucose control, and CPP-guided therapy)65(.)]TJ
0 -1.15789 TD
0.126 Tw
(Interventions that were employed in selected patients included)Tj
0 -1.1579 TD
0.02 Tc
0.505 Tw
(the EVD, mannitol, hyperventilation, hypertonic saline,)Tj
T*
0.446 Tw
(neuromuscular blockade, and sedation with propofol or)Tj
T*
0 Tc
-0.001 Tw
(narcotics. Sur)Tj
5.72699 0.00001 TD
(gery was rarely used in DAI, but was occasionally)Tj
-5.72699 -1.1579 TD
0.07 Tw
[(used in patients with IC. )18(The JVO was reported as rarely used)]TJ
0 -1.15789 TD
0.025 Tw
(for patients with either DAI or IC.)Tj
1.26316 -1.15789 TD
0.115 Tw
[(In )18(T)70(ables 4, 5, and 6, the correlations between the reported)]TJ
-1.26316 -1.15789 TD
0.066 Tw
(appropriateness and frequency of use of each intervention were)Tj
0 -1.1579 TD
-0.036 Tw
(considered in EPI, DAI, and IC. In general, the correlations were)Tj
0 -1.15789 TD
0.019 Tw
[(very high (p < 0.0001) between each intervention and itself. )55(An)]TJ
T*
0.058 Tw
(exception noted was the use of the JVO, which was reported to)Tj
0 -1.1579 TD
0.025 Tw
(be appropriate more frequently than it was actually used in each)Tj
0 -1.15789 TD
0.206 Tw
(of the scenarios. Close correlations were noted between the)Tj
T*
0.1 Tw
(reported appropriateness and frequency of use of mannitol and)Tj
0 -1.1579 TD
0.147 Tw
(hypertonic saline, and generally between early enteral feeding)Tj
0 -1.15789 TD
0.2 Tw
[(and intensive glucose control )55(As well, CPP-guided therapy)]TJ
T*
-0.015 Tw
(correlated closely with the recommendation and use of mannitol.)Tj
0 -1.1579 TD
0.176 Tw
[(Surprisingly)65(, the correlation between CPP-guided therapy and)]TJ
0 -1.15789 TD
0.237 Tw
[(the use of the EVD was weak. )55(Although clinicians reported)]TJ
T*
0.083 Tw
(intensive insulin therapy to be appropriate, the correlation with)Tj
0 -1.1579 TD
0.152 Tw
(its frequency of use was very weak. Otherwise, few positive)Tj
0 -1.15789 TD
0.069 Tw
(correlations between reported appropriateness and frequency of)Tj
T*
0.025 Tw
(use were noted. )Tj
ET
0 0 0 0 k
39.024 726 516 30 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9 0 0 9 308.5412 749.8455 Tm
0 0 0 1 k
0.025 Tw
[(LE JOURNAL)-238(CANADIEN DES SCIENCES NEUROLOGIQUES)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
9 0 0 9 39.024 29.4312 Tm
0 0 0 1 k
0.025 Tw
[(V)111(olume 34, No. 3 \320 )18(August 2007)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9 0 0 9 540.524 29.4312 Tm
0 0 0 1 k
(309)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 40.024 708.3234 Tm
0 0 0 1 k
0.001 Tc
0.025 Tw
[(T)92(able 2: Summar)1(y Ranking of Interventions)]TJ
3.78947 -1.15789 TD
[(Appr)19(opriateness \(Mean Scor)19(e)-1(\))]TJ
ET
1 w
0 0 0 1 K
39.024 546.356 m
286.2 546.356 l
S
39.024 721.885 m
286.2 721.885 l
S
0.5 w
39.024 688.885 m
286.2 688.885 l
S
/GS2 gs
q
39.024 546.5259 247.176 141.895 re
W n
/Fm2 Do
Q
/GS1 gs
BT
/F1 1 Tf
9.5 0 0 9.5 40.024 200.5034 Tm
[(T)92(able 3: Summar)1(y Ranking of Interventions)]TJ
3.78947 -1.15789 TD
[(F)-1(r)19(equency \(Mean Sc)-1(or)19(e)-1(\))]TJ
ET
1 w
39.024 71.5369 m
286.2 71.5369 l
S
39.024 214.065 m
286.2 214.065 l
S
0.5 w
39.024 181.0649 m
286.2 181.0649 l
S
/GS2 gs
q
39.024 71.648 247.176 108.953 re
W n
/Fm4 Do
Q
Q
endstream
endobj
34 0 obj
<<
/Filter /FlateDecode
/Length 238
>>
stream
xmK0[n*8rdI&ulvLnu^Z /{bI/ӻX_q_/pZim>VR+.c,| Dcw#O*T V8Ux]t62[lxBk3j9nj4sgu99<.0Sy-ǠVyC>,^Ǝ=64hNqz8
(r+~mZ
77z
endstream
endobj
35 0 obj
<<
/Type /Annot
/Subtype /Link
/Rect [7.7999997 14.264648 133.62 22.189453]
/Border [0 0 0]
/A 67 0 R
>>
endobj
36 0 obj
<<
/Name /Fm6
/BBox [0 0 593.99994 782.99994]
/Subtype /Form
/Resources <<
/XObject <<
/Fm7 68 0 R
>>
/ProcSet [/PDF]
/ExtGState <<
/GS3 63 0 R
>>
>>
/Type /XObject
/Length 62
/Matrix [1 0 0 1 0 0]
/OPI <<
/1.3 <<
/ImageType [1 1]
/Resolution [300 300]
/Version 1.3
/Size [2072 928]
/CropRect [31 36 2012 910]
/CropFixed [31.336 36.238 2011.88501 909.98199]
/Overprint false
/Type /OPI
/F (Production-HD:Users:Production:Production Documents:Production Documents: Journal in Progress: 34#3 Aug 2007:figures tables:3128 Table 4.tif)
/ColorType /Process
/Position [39.024 577.55603 39.024 686.60101 286.20001 686.60101 286.20001 577.55603]
/Color [0 0 0 1 (Black)]
>>
>>
/FormType 1
>>
stream
/GS3 gs
q
247.57622 0 0 109.4376 38.857 577.3184 cm
/Fm7 Do
Q
endstream
endobj
37 0 obj
<<
/Name /Fm8
/BBox [0 0 593.99994 782.99994]
/Subtype /Form
/Resources <<
/XObject <<
/Fm9 69 0 R
>>
/ProcSet [/PDF]
/ExtGState <<
/GS3 63 0 R
>>
>>
/Type /XObject
/Length 63
/Matrix [1 0 0 1 0 0]
/OPI <<
/1.3 <<
/ImageType [1 1]
/Resolution [300 300]
/Version 1.3
/Size [1968 988]
/CropRect [36 18 1908 952]
/CropFixed [35.555 17.778 1908.26294 952.41101]
/Overprint false
/Type /OPI
/F (Production-HD:Users:Production:Production Documents:Production Documents: Journal in Progress: 34#3 Aug 2007:figures tables:3128 Table 5.tif)
/ColorType /Process
/Position [307.79999 563.23999 307.79999 686.60101 554.97601 686.60101 554.97601 563.23999]
/Color [0 0 0 1 (Black)]
>>
>>
/FormType 1
>>
stream
/GS3 gs
q
247.61052 0 0 123.8052 307.595 563.0298 cm
/Fm9 Do
Q
endstream
endobj
38 0 obj
<<
/Name /Fm10
/BBox [0 0 593.99994 782.99994]
/Subtype /Form
/Resources <<
/XObject <<
/Fm11 70 0 R
>>
/ProcSet [/PDF]
/ExtGState <<
/GS3 63 0 R
>>
>>
/Type /XObject
/Length 61
/Matrix [1 0 0 1 0 0]
/OPI <<
/1.3 <<
/ImageType [1 1]
/Resolution [300 300]
/Version 1.3
/Size [1896 988]
/CropRect [24 28 1831 959]
/CropFixed [24.272 27.83 1831.18103 958.93298]
/Overprint false
/Type /OPI
/F (Production-HD:Users:Production:Production Documents:Production Documents: Journal in Progress: 34#3 Aug 2007:figures tables:3128 Table 6.tif)
/ColorType /Process
/Position [307.79999 65.293 307.79999 194.894 554.97601 194.894 554.97601 65.293]
/Color [0 0 0 1 (Black)]
>>
>>
/FormType 1
>>
stream
/GS3 gs
q
247.599 0 0 130.0041 307.626 65.1448 cm
/Fm11 Do
Q
endstream
endobj
39 0 obj
<<
/Filter /FlateDecode
/Length 10
>>
stream
x+ |
endstream
endobj
40 0 obj
<<
/Length 8209
>>
stream
/GS0 gs
1 g
0 783 0 0 re
f
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 40.024 496.5035 Tm
0 0 0 1 k
(D)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.125 0 0 7.125 46.8823 496.5035 Tm
0 0 0 1 k
0.001 Tc
(ISCUSSION)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 52.024 481.5035 Tm
0 0 0 1 k
0.295 Tw
(In this Canadian cross-sectional survey of intensive care)Tj
-1.26316 -1.15789 TD
0.272 Tw
(physicians and neurosur)Tj
10.18866 0 TD
(geons that treat patients with severe)Tj
-10.18866 -1.1579 TD
0.078 Tw
(closed head injury)Tj
7.42073 0 TD
-0.0001 Tc
(,)Tj
0.57738 0 Td
0 Tc
(57% of eligible respondents replied \(141 of)Tj
-7.99811 -1.1579 TD
0.044 Tw
[(247\). )18(These physicians replied from 29 of 31 sites identified in)]TJ
0 -1.15789 TD
0.298 Tw
(Canada as receiving and treating patients with severe CHI.)Tj
0 -1.1579 TD
0.111 Tw
[(Consequently)65(, this survey provides a broad examination of the)]TJ
T*
0.025 Tw
(Canadian management of patients with severe CHI.)Tj
1.26316 -1.15789 TD
0.011 Tc
0.364 Tw
[(W)40(ith its scenario-based design (Appendix 1), areas of)]TJ
-1.26316 -1.1579 TD
0 Tc
0.141 Tw
[(agreement, disagreement, and uncertainty were identified. )18(The)]TJ
T*
0.134 Tw
(scenarios represented acute and subacute situations of patients)Tj
0 -1.15789 TD
0.118 Tw
(with severe CHI, which represented most of those realistically)Tj
0 -1.1579 TD
0.035 Tw
(available. Certain therapies were considered by the expert panel)Tj
T*
-0.021 Tw
(as to be so simple or sensible \(e.g. head kept in neutral alignment)Tj
0 -1.15789 TD
0.194 Tw
(with neck, elevation of head of bed\) that testing in a survey)Tj
0 -1.1579 TD
0.168 Tw
[(would have been redundant, and were not of)18(fered as options.)]TJ
T*
0.115 Tw
(Other promising manoeuvres such as microdialysis assessment)Tj
0 -1.15789 TD
0.173 Tw
(remain primarily investigational, and were not entered on the)Tj
0 -1.1579 TD
0 Tw
(survey)Tj
2.60059 0 TD
(.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 67.1046 297.6386 Tm
0 0 0 1 k
(7)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 73.3532 294.5035 Tm
0 0 0 1 k
(Conversely)Tj
4.48925 0 TD
-0.0001 Tc
(,)Tj
0.57762 0 Td
0 Tc
0.078 Tw
[(although sur)18(gery was an option in each of)]TJ
-8.57521 -1.1579 TD
0.089 Tw
(the scenarios considered, this was only considered in a general)Tj
0 -1.15789 TD
0.242 Tw
(sense. Comprehensive and detailed evaluation of the role of)Tj
0 -1.1579 TD
0.025 Tw
[(sur)18(gery in severe CHI was beyond the scope of this survey)65(.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 267.1498 264.6386 Tm
0 0 0 1 k
(8,9)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 52.024 250.5035 Tm
0 0 0 1 k
0.02 Tc
0.405 Tw
(The first acute scenario described a patient with an)Tj
-1.26316 -1.1579 TD
0.019 Tc
0.356 Tw
[(intracranial epidural hematoma and signs of mass ef)18(fect)]TJ
0 -1.15789 TD
0.004 Tc
0.371 Tw
((Appendix 1). Respondents agreed extremely strongly that)Tj
T*
0 Tc
0 Tw
(sur)Tj
1.20385 0.00001 TD
0.323 Tw
(gery was appropriate, and reported performing it almost)Tj
-1.20385 -1.15791 TD
0.023 Tw
[(always in such patients. )18(They agreed very strongly that steroids)]TJ
0 -1.15789 TD
[(were inappropriate in this setting. )18(This consensus supported the)]TJ
T*
0.008 Tc
0.367 Tw
(face and content validity of the survey)Tj
17.76275 0.00001 TD
0.0075 Tc
(.)Tj
0.8824 0 Td
0.008 Tc
(Furthermore, the)Tj
-18.64515 -1.15791 TD
0.02 Tc
0.497 Tw
(consensus against steroids is supported by randomized)Tj
0 -1.15789 TD
0 Tc
0 Tw
(evidence.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 76.1546 165.6386 Tm
0 0 0 1 k
(10)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 52.024 151.5035 Tm
0 0 0 1 k
0.02 Tc
0.395 Tw
(Surprisingly in the EPI scenario, clinicians classified)Tj
-1.26316 -1.1579 TD
0 Tc
0.241 Tw
(hyperventilation as of uncertain appropriateness, in a patient)Tj
0 -1.15789 TD
0.175 Tw
[(with a space-occupying lesion and mass ef)18(fect. )55(Although this)]TJ
T*
0.02 Tc
0.421 Tw
(may reflect the harm observed in a trial of long-term)Tj
0 -1.1579 TD
0 Tc
0.069 Tw
(hyperventilation after CHI,)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 144.4597 110.6386 Tm
0 0 0 1 k
(1)Tj
0.44415 0.00001 TD
(1,12)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 161.243 107.5034 Tm
0 0 0 1 k
0.069 Tw
(the evidence from the cited trial)Tj
-12.75989 -1.15789 TD
-0.022 Tw
(would have been misapplied in this scenario. It may alternatively)Tj
T*
0.183 Tw
(reflect a limitation of survey design, survey interpretation, or)Tj
T*
0.236 Tw
(uncertainty about the timing of therapy)Tj
16.74697 0.00001 TD
-0.0001 Tc
(.)Tj
0.73549 0 Td
0 Tc
0 Tw
(Finally)Tj
2.76849 0.00001 TD
-0.0001 Tc
(,)Tj
0.7355 0 Td
0 Tc
0.236 Tw
(it may also)Tj
-20.98644 -1.15791 TD
-0.007 Tw
(reflect a limitation of study interpretation. In regard to the latter)Tj
25.59588 0.00001 TD
(,)Tj
2.73422 44 TD
-0.009 Tw
(although the overall average interpretation of hyperventilation in)Tj
0 -1.15789 TD
0.319 Tw
(EPI was \324uncertain\325, clinicians may have been much more)Tj
0 -1.1579 TD
0.026 Tw
(certain as individuals although dif)Tj
13.69336 0 TD
(fering from one another in the)Tj
-13.69336 -1.1579 TD
0.025 Tw
(grouped assessment.)Tj
1.26316 -1.15789 TD
0.152 Tw
(Clinicians agreed on the appropriateness of osmotic agents)Tj
-1.26316 -1.1579 TD
-0.015 Tw
[(such as mannitol and hypertonic saline \(T)70(able 2\). However)39(, they)]TJ
T*
0.158 Tw
(reported using hypertonic saline less frequently than mannitol)Tj
0 -1.15789 TD
0.198 Tw
[(\(T)69(able 3\). )18(This may reflect a greater general familiarity with)]TJ
0 -1.1579 TD
0.001 Tc
0.374 Tw
[(mannitol, dif)18(ferential access, or other factors. Nonetheless,)]TJ
T*
0 Tc
0.014 Tw
[(mannitol and hypertonic saline have dif)18(ferent durations of ef)17(fect)]TJ
0 -1.15789 TD
0.074 Tw
(and side ef)Tj
4.46039 0 TD
(fect profiles, and it is reasonable to hypothesize that)Tj
-4.46039 -1.1579 TD
0.136 Tw
(they may also have dif)Tj
9.57834 0 TD
(ferent ef)Tj
3.47582 0 TD
(fectiveness. Some preliminary)Tj
-13.05416 -1.1579 TD
0.018 Tc
0.357 Tw
[(evidence has suggested a longer duration of ef)18(fect with)]TJ
0 -1.15789 TD
0 Tc
-0.031 Tw
(hypertonic saline than with mannitol when the intent is control of)Tj
0 -1.1579 TD
0.261 Tw
(intracranial hypertension.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 408.7003 330.6386 Tm
0 0 0 1 k
(13 )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 418.1721 327.5035 Tm
0 0 0 1 k
0.261 Tw
(Given the variability in clinician-)Tj
-11.47496 -1.1579 TD
0.281 Tw
(reported appropriateness and frequency of use of these two)Tj
0 -1.15789 TD
0.025 Tw
(therapies, further investigation would be beneficial.)Tj
ET
0 0 0 0 k
39.696 726 516 30 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9 0 0 9 39.696 749.8455 Tm
0 0 0 1 k
-0.0001 Tc
(THE)Tj
2.21865 0 Td
0 Tc
0.025 Tw
[(CANADIAN JOURNAL)-238(OF NEUROLOGICAL)-238(SCIENCES)]TJ
-2.21865 -80.04603 TD
(310)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 40.024 706.5035 Tm
0 0 0 1 k
0.001 Tc
0.093 Tw
[(T)92(able 4: Corr)18(elations of )56(Appr)19(opriateness and Fr)19(equency of)]TJ
1.26316 -1.15789 TD
0.025 Tw
(Use of Interventions: Epidural Hematyoma)Tj
ET
1 w
0 0 0 1 K
39.024 577.537 m
286.2 577.537 l
S
39.024 720.0649 m
286.2 720.0649 l
S
0.5 w
39.024 687.0649 m
286.2 687.0649 l
S
/GS2 gs
q
39.024 577.556 247.176 109.045 re
W n
/Fm6 Do
Q
/GS1 gs
BT
/F1 1 Tf
9.5 0 0 9.5 308.8 706.5035 Tm
0.093 Tw
[(T)92(able 5: Corr)18(elations of )56(Appr)19(opriateness and Fr)19(equency of)]TJ
1.26315 -1.15789 TD
0.025 Tw
[(Use of Interventions: Dif)1(fuse )56(Axonal Injury)]TJ
ET
1 w
307.8 563.5369 m
554.976 563.5369 l
S
307.8 720.0649 m
554.976 720.0649 l
S
0.5 w
307.8 687.0649 m
554.976 687.0649 l
S
/GS2 gs
q
307.8 563.2399 247.176 123.361 re
W n
/Fm8 Do
Q
/GS1 gs
BT
/F1 1 Tf
9.5 0 0 9.5 308.8 214.7967 Tm
0 Tc
(T)Tj
0.5752 0.00001 TD
0.001 Tc
0.093 Tw
(able 6: Corr)Tj
5.38884 0.00001 TD
[(elations of )56(Appr)19(opriateness and Fr)18(equency of)]TJ
-4.70089 -1.15791 TD
0.025 Tw
(Use of Interventions: Intracranial Contrusion)Tj
ET
1 w
307.8 64.793 m
554.976 64.793 l
S
307.8 228.358 m
554.976 228.358 l
S
0.5 w
307.8 195.358 m
554.976 195.358 l
S
/GS2 gs
q
307.8 65.293 247.176 129.6009 re
W n
/Fm10 Do
Q
Q
endstream
endobj
41 0 obj
<<
/Filter /FlateDecode
/Length 238
>>
stream
xmK0[n*8rdI&ulvLnu^Z /{bJ/ӻX_q_/pZim>VR+.c,| Dcw#O*T V8Ux]t62[lxBk3j9nj4sgu99<.0Sy-ǠVyC>,^Ǝ=64hNqz8
(r+~mZ
77x
endstream
endobj
42 0 obj
<<
/Type /Annot
/Subtype /Link
/Rect [7.7999997 14.264648 133.62 22.189453]
/Border [0 0 0]
/A 71 0 R
>>
endobj
43 0 obj
<<
/Filter /FlateDecode
/Length 10
>>
stream
x+ |
endstream
endobj
44 0 obj
<<
/Length 12411
>>
stream
/GS0 gs
1 g
0 783 0 0 re
f
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 52.024 717.024 Tm
0 0 0 1 k
0.342 Tw
(Cooling was of uncertain appropriateness and was used)Tj
-1.26316 -1.1579 TD
0.04 Tw
[(occasionally)65(, and this probably reflects the group opinion of the)]TJ
0 -1.15789 TD
0.171 Tw
[(diversity of patients with severe CHI treated. )18(While the most)]TJ
T*
0.179 Tw
(methodologically sound evidence does not support systematic)Tj
0 -1.1579 TD
0.027 Tw
(cooling of all patients with severe CHI, some room for clinician)Tj
0 -1.15789 TD
-0.0001 Tc
(d)Tj
0.49988 -0.00001 TD
0 Tc
0.112 Tw
(iscretion remains.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 113.3626 665.159 Tm
0 0 0 1 k
(14,15)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 134.3471 662.024 Tm
0 0 0 1 k
-0.0001 Tc
(C)Tj
0.66693 -0.00001 TD
0 Tc
0.112 Tw
(ooling, to be beneficial, would apply)Tj
-10.59568 -1.15789 TD
0.128 Tw
(particularly in the younger patient with generalized and rapid-)Tj
T*
0.009 Tw
[(onset intracranial hypertension, and in the absence of sur)18(gically-)]TJ
0 -1.1579 TD
0.073 Tw
[(correctable pathology)65(. Conversely)65(, cooling would be less likely)]TJ
0 -1.15789 TD
0.145 Tw
(to benefit if applied later in the course of therapy to an older)Tj
T*
0 Tw
(patient.)Tj
1.26316 -1.1579 TD
0.375 Tw
(The uncertain appropriateness, and only occasional use,)Tj
-1.26316 -1.15789 TD
0.304 Tw
[(attributed to phenytoin in EPI was somewhat surprising. )55(A)]TJ
T*
0.166 Tw
(limited course of phenytoin has been suggested to reduce the)Tj
0 -1.1579 TD
0.035 Tw
(incidence of early post-traumatic convulsions, although the data)Tj
0 -1.15789 TD
0.16 Tw
[(on this topic are limited, and no ef)18(fect on mortality has been)]TJ
T*
0 Tw
(reported.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 74.044 544.1589 Tm
0 0 0 1 k
(16)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 86.0318 541.024 Tm
0 0 0 1 k
0.352 Tw
(Given the uncertainty found among respondents)Tj
-4.84293 -1.1579 TD
0.006 Tw
(about the appropriate role of phenytoin, its potential benefit, and)Tj
T*
0.023 Tw
(the availability of anticonvulsants with more favourable adverse)Tj
0 -1.15789 TD
0 Tw
(ef)Tj
0.75879 -0.00001 TD
0.025 Tw
(fect profiles, further study may be beneficial.)Tj
0.50437 -1.15788 TD
0.203 Tw
(In the two other scenarios, clinicians were presented with)Tj
-1.26316 -1.15789 TD
0.094 Tw
(situations that suggested intracranial contusion \(IC \320 )Tj
21.90229 0 TD
0 Tw
(Appendix)Tj
-21.90229 -1.1579 TD
0.018 Tc
0.357 Tw
[(1\) and dif)18(fuse axonal injury and traumatic subarachnoid)]TJ
0 -1.15789 TD
0 Tc
0.09 Tw
(hemorrhage \(DAI - )Tj
8.18098 0 TD
(Appendix 1\). Management of patients with)Tj
-8.18098 -1.1579 TD
0.145 Tw
[(these injuries was reported to be very similar)40(, as expected. In)]TJ
0 -1.15789 TD
0.333 Tw
(general, considering the correlations of appropriateness and)Tj
0 -1.1579 TD
0.007 Tw
(frequency of use, interventions that were reported as appropriate)Tj
T*
0.235 Tw
[(were also commonly used \(T)70(ables 4, 5 and 6\). Respondents)]TJ
0 -1.15789 TD
0.076 Tw
(agreed strongly on the appropriateness of early enteral feeding,)Tj
0 -1.1579 TD
0.043 Tw
[(intensive insulin therapy for glucose control, reduction of fever)40(,)]TJ
T*
0.23 Tw
[(and CPP-guided therapy)65(. Clinicians agreed, but less strongly)]TJ
0 -1.15789 TD
0.128 Tw
(than in EPI, that osmotic diuretics were appropriate. )Tj
22.0683 0 TD
0 Tw
(Although)Tj
-22.0683 -1.1579 TD
0.052 Tw
(monitoring with the EVD and JVO were appropriate, the actual)Tj
T*
0.025 Tw
(use of JVO was only occasional or rare. )Tj
1.26316 -1.15789 TD
0.009 Tc
0.366 Tw
(In both DAI and IC, respondents reported the use of)Tj
-1.26316 -1.1579 TD
0 Tc
0.233 Tw
(hyperventilation to be of uncertain appropriateness, which is)Tj
T*
0.061 Tw
[(consistent with published results. )18(This contrasts somewhat with)]TJ
0 -1.15789 TD
-0.003 Tw
[(the respondents\325)-173(opinion about hyperventilation in EPI, although)]TJ
0 -1.1579 TD
0.125 Tw
(this dif)Tj
2.91245 0 TD
(ference may be due to survey interpretation rather than)Tj
-2.91245 -1.1579 TD
0.002 Tc
0.373 Tw
(practice variation. Clarification of the explanation for this)Tj
T*
0 Tc
0.025 Tw
[(dif)18(ference would be beneficial.)]TJ
1.26316 -1.15789 TD
0.083 Tw
[(While most \324appropriate\325)-259(interventions were also commonly)]TJ
-1.26316 -1.15789 TD
0.062 Tw
(used, relatively few interventions were used in association with)Tj
0 -1.1579 TD
0.01 Tw
[(other interventions. For example, sur)18(gery was closely associated)]TJ
0 -1.15789 TD
-0.035 Tw
(with EVD use in EPI, but little else. Both the EVD and JVO were)Tj
T*
0.105 Tw
(appropriate, and correlated with each other as well as with the)Tj
0 -1.1579 TD
0.002 Tw
[(use of CPP-directed therapy)65(. However)40(, the JVO was rarely used.)]TJ
0 -1.15789 TD
0.012 Tw
(In practice, the EVD is both diagnostic and therapeutic, whereas)Tj
T*
-0.003 Tw
[(the JVO is of diagnostic use only)65(. )18(The EVD is also necessary for)]TJ
0 -1.1579 TD
-0.006 Tw
[(CPP-directed therapy)65(, which had been reported to be appropriate)]TJ
0 -1.15789 TD
-0.0001 Tc
(by)Tj
1.28274 0 Td
(a)Tj
0.72682 0 Td
0 Tc
0.033 Tw
(majority of respondents. Existing guidelines support use of)Tj
-2.00957 -1.15789 TD
0.018 Tw
(the EVD in patients with severe CHI and abnormalities detected)Tj
0 -1.1579 TD
0.025 Tw
[(on CT)-257(scan.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 85.9719 148.159 Tm
0 0 0 1 k
(4)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 52.024 134.024 Tm
0 0 0 1 k
0.02 Tc
0.355 Tw
(The appropriateness of CPP-guided therapy and EVD)Tj
-1.26316 -1.15789 TD
0.01 Tc
0.365 Tw
(placement was high in patients with DAI or IC, and in)Tj
0 -1.1579 TD
0 Tc
0.134 Tw
(accordance with guidelines.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 148.3459 115.159 Tm
0 0 0 1 k
(4)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 155.1325 112.0239 Tm
0 0 0 1 k
0.134 Tw
[(Surprisingly)65(, CPP-guided therapy)]TJ
-12.11668 -1.15789 TD
0.071 Tw
[(was rated as more appropriate than EVD placement. Moreover)40(,)]TJ
T*
-0.024 Tw
(only minimal correlation between appropriateness and frequency)Tj
0 -1.1579 TD
0.024 Tw
[(of use was seen between these two interventions. )18(This raises the)]TJ
28.33011 67.15777 TD
0.071 Tw
(suspicion that EVD use is less frequent than optimal, given the)Tj
0 -1.15789 TD
0.002 Tc
0.373 Tw
(physiologic impossibility of delivering CPP-guided therapy)Tj
T*
0.02 Tc
0.576 Tw
(without knowledge of the intracranial pressure (ICP).)Tj
0 -1.1579 TD
0 Tc
0.084 Tw
[(Alternatively)65(, clinicians may be delivering CPP-guided therapy)]TJ
0 -1.15789 TD
0.329 Tw
[(based on an assumed ICP)111(, without its direct measurement.)]TJ
T*
0.02 Tc
0.43 Tw
(Although clinicians may be using alternative means of)Tj
0 -1.1579 TD
0 Tc
0.169 Tw
[(measuring intracranial pressures e.g. parenchymal manometer)40(,)]TJ
0 -1.15789 TD
0.123 Tw
(none have the same diagnostic and therapeutic capacity as the)Tj
T*
0.025 Tw
(EVD, which remains the gold standard.)Tj
1.26316 -1.1579 TD
0.324 Tw
(Clinicians reported that the use of early enteral feeding)Tj
-1.26316 -1.15789 TD
0.001 Tc
0.374 Tw
((immediately post-admission) and intensive glucose control)Tj
T*
0 Tc
0.226 Tw
[(were very appropriate. )18(W)40(ith respect to early enteral feeding,)]TJ
0 -1.1579 TD
0.137 Tw
[(clinicians\325)-314(use is supported by a recent systematic review that)]TJ
0 -1.15789 TD
0.136 Tw
(revealed a relative risk for death with early enteral feeding of)Tj
T*
0.105 Tw
(0.67 (95% CI 0.41-1.07).)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 407.9151 566.1578 Tm
0 0 0 1 k
(17)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 417.5559 563.0228 Tm
0 0 0 1 k
0.105 Tw
[(However)40(, intensive glucose control)]TJ
-11.41009 -1.1579 TD
0.034 Tw
(was much more appropriate than its estimated frequency of use.)Tj
0 -1.15789 TD
0.085 Tw
(Given that the original study demonstrating the benefit of tight)Tj
T*
0.364 Tw
(glucose control among the critically ill included very few)Tj
0 -1.1579 TD
0.083 Tw
(neurologically-impaired patients,)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 436.0408 522.1578 Tm
0 0 0 1 k
(1)Tj
0.5 -0.00001 TD
(8)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 445.4783 519.0228 Tm
0 0 0 1 k
0.083 Tw
(clinicians may be indicating)Tj
-14.3493 -1.15789 TD
0.025 Tw
(some reservation about applying this evidence in their practice. )Tj
1.26316 -1.15789 TD
0 Tw
[(Neurosur)18(geons and intensive care physicians reported similar)]TJ
-1.26316 -1.1579 TD
0.249 Tw
(practice attitudes in most scenarios. )Tj
15.68505 0 TD
(Among the few notable)Tj
-15.68505 -1.1579 TD
0.085 Tw
[(dif)18(ferences were a greater preference among neurosur)17(geons for)]TJ
T*
0.132 Tw
(the use of mannitol, and a greater preference among intensive)Tj
0 -1.15789 TD
0.014 Tw
(care physicians for the use of early enteral feeding and intensive)Tj
0 -1.1579 TD
-0.031 Tw
[(insulin therapy)65(. Since uncertainty remains about the true ef)18(fect of)]TJ
T*
0.225 Tw
(these therapies on the outcome of patients with severe CHI,)Tj
0 -1.15789 TD
0.025 Tw
(further evaluation would be beneficial.)Tj
1.26316 -1.1579 TD
0.016 Tw
(Limitations of this survey are several. In general, a survey is)Tj
-1.26316 -1.1579 TD
0.26 Tw
(limited in size because of the time required to complete it.)Tj
0 -1.15789 TD
0.02 Tc
0 Tw
(Consequently)Tj
5.67429 0 TD
0.0199 Tc
(,)Tj
0.923 0 Td
0.02 Tc
0.383 Tw
(it was not possible to investigate all the)Tj
-6.59729 -1.1579 TD
0 Tc
0.264 Tw
(permutations of clinical scenarios that might af)Tj
20.39091 0 TD
(fect clinician)Tj
-20.39091 -1.1579 TD
0.018 Tw
[(judgement, including especially dose and duration of therapy)65(, or)]TJ
0 -1.15789 TD
0.15 Tw
(relative priorities of therapies. )Tj
12.84227 0 TD
(A)Tj
1.06653 0 TD
(survey is not a surrogate for)Tj
-13.9088 -1.1579 TD
0.034 Tw
(definitive outcome data, although it serves to illustrate variation)Tj
T*
0.254 Tw
[(in practice and attitude. Finally)65(, the survey results represent)]TJ
0 -1.15789 TD
-0.036 Tw
[(averaged group opinions, and not individual opinions. )18(This latter)]TJ
0 -1.1579 TD
0.02 Tc
0.543 Tw
(point is important in the interpretation of \324uncertain\325)Tj
T*
0.009 Tc
0.366 Tw
[(appropriateness. \324Uncertain\325)-551(in this context could also be)]TJ
T*
0 Tc
0.067 Tw
(interpreted to mean \324neither appropriate nor inappropriate\325, and)Tj
0 -1.15789 TD
0.054 Tw
[(must be understood to represent a group average. \324Uncertain\325)-230(is)]TJ
T*
0.045 Tw
[(not synonymous with \324do not know\325)-221(on an individual basis, and)]TJ
T*
0.025 Tw
(simply relates to variation of opinion among the respondents.)Tj
1.26316 -1.15789 TD
(W)Tj
0.90405 0.00001 TD
0.107 Tw
(ithin the limits of study design, this survey has described)Tj
-2.16721 -1.15791 TD
0.049 Tw
(current practice with regard to treatment of patients with severe)Tj
0 -1.15789 TD
0.219 Tw
(CHI, and identified areas of variation that may benefit from)Tj
T*
0 Tw
(further evaluation. In the EPI scenario, a patient virtually always)Tj
0 -1.1579 TD
0.173 Tw
[(requires sur)18(gery)65(, and frequently EVD placement. In the more)]TJ
0 -1.15789 TD
0.049 Tw
(subacute settings of DAI and IC, consensus was best in support)Tj
T*
0.247 Tw
[(of CPP-directed therapy)65(, early enteral feeding, and intensive)]TJ
0 -1.1579 TD
0.017 Tw
[(insulin therapy)65(. However)40(, EVD placement may be less frequent)]TJ
0 -1.15789 TD
0.181 Tw
[(than the use of CPP-guided therapy)65(, which is physiologically)]TJ
T*
0 Tw
(dif)Tj
1.09277 0.00001 TD
0.141 Tw
(ficult, and should be further evaluated. Finally)Tj
19.33151 0.00001 TD
-0.0001 Tc
(,)Tj
0.64109 0 Td
0 Tc
(the roles of)Tj
-21.06536 -1.15791 TD
0.253 Tw
(hypertonic saline and mannitol in the control of intracranial)Tj
0 -1.15789 TD
0.064 Tw
(hypertension should be better defined. Randomized prospective)Tj
T*
0.086 Tw
(evaluation of these therapies will help to direct treatment more)Tj
0 -1.1579 TD
0 Tw
[(ef)17(fectively)65(. )]TJ
ET
0 0 0 0 k
39.024 726 516 30 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9 0 0 9 308.5412 749.8455 Tm
0 0 0 1 k
0.025 Tw
[(LE JOURNAL)-238(CANADIEN DES SCIENCES NEUROLOGIQUES)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F3 1 Tf
9 0 0 9 39.024 29.4312 Tm
0 0 0 1 k
0.025 Tw
[(V)111(olume 34, No. 3 \320 )18(August 2007)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9 0 0 9 540.524 29.4312 Tm
0 0 0 1 k
(311)Tj
ET
Q
endstream
endobj
45 0 obj
<<
/Filter /FlateDecode
/Length 238
>>
stream
xmK0[n*8rdI&ulvLnu^Z /{bI/ӻX_q_/pZim>VR+.c,| Dcw#O*T V8Ux]t62[lxBk3j9nj4sgu99<.0Sy-ǠVyC>,^Ǝ=64hNqz8
(r+~mZ
77z
endstream
endobj
46 0 obj
<<
/Type /Annot
/Subtype /Link
/Rect [7.7999997 14.264648 133.62 22.189453]
/Border [0 0 0]
/A 72 0 R
>>
endobj
47 0 obj
<<
/Filter /FlateDecode
/Length 10
>>
stream
x+ |
endstream
endobj
48 0 obj
<<
/Length 6533
>>
stream
/GS0 gs
1 g
0 783 0 0 re
f
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 40.024 717.0228 Tm
0 0 0 1 k
(R)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.125 0 0 7.125 46.8823 717.0228 Tm
0 0 0 1 k
0.0011 Tc
(E)Tj
0.66706 -0.00001 TD
0.001 Tc
(FERENCES)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
8.5 0 0 8.5 40.024 704.0228 Tm
0 0 0 1 k
(1)Tj
0.5 -0.00001 TD
-0.022 Tw
[(.)-1132(Zygun DA, Laupland KB, Hader )17(WJ, Kortbeek JB, Findlay C, Doig)]TJ
2.55883 -1.05882 TD
-0.026 Tw
[(CJ, et al. Severe traumatic brain injury in a lar)18(ge Canadian health)]TJ
T*
0.025 Tw
(region. Can J Neurol Sci. 2005;32(1):87-92.)Tj
-3.05882 -1.05882 TD
0.076 Tw
[(2.)-1132(Price SJ, Suttner N, )54(Aspoas )55(AR. Have )55(A)111(TLS and national transfer)]TJ
3.05882 -1.05882 TD
0.084 Tw
(guidelines improved the quality of resuscitation and transfer of)Tj
T*
0.274 Tw
[(head-injured patients? )55(A)-470(prospective survey from a regional)]TJ
T*
0.025 Tw
[(neurosur)18(gical unit. Injury)65(. 2003;34\(1)36(1\):834-8.)]TJ
-3.05882 -1.05882 TD
0.104 Tw
[(3.)-1132(Sekula RF)79(, Jr)55(., )18(W)40(ilber)18(ger JE. )17(The management of traumatic brain)]TJ
3.05882 -1.05882 TD
-0.0001 Tc
(i)Tj
0.27791 -0.00001 TD
0 Tc
0.108 Tw
(njury: the development of guidelines and their influence. Clin)Tj
-0.27791 -1.05882 TD
0.025 Tw
[(Neurosur)18(g. 2005;52:306-10.)]TJ
-3.05882 -1.05882 TD
0.083 Tw
[(4.)-1132(Guidelines for the management of severe traumatic brain injury)64(. J)]TJ
3.05882 -1.05882 TD
0.025 Tw
(Neurotrauma. 2000;17(6/7):450-553.)Tj
-3.05882 -1.05882 TD
0.205 Tw
[(5.)-1132(Bulger EM, Nathens )55(AB, Rivara FP)110(, Moore M, MacKenzie EJ,)]TJ
3.05882 -1.05882 TD
0.119 Tw
(Jurkovich GJ. Management of severe head injury: institutional)Tj
T*
0.364 Tw
[(variations in care and ef)18(fect on outcome. Crit Care Med.)]TJ
T*
0 Tw
(2002;30(8):1870-6.)Tj
-3.05882 -1.05882 TD
(6)Tj
0.5 -0.00001 TD
0.202 Tw
[(.)-1132(Kerr J, Smith R, Gray S, Beard D, Robertson CE. )55(An audit of)]TJ
2.55883 -1.05882 TD
0.244 Tw
(clinical practice in the management of head injured patients)Tj
T*
0.02 Tc
0.357 Tw
(following the introduction of the Scottish Intercollegiate)Tj
T*
0 Tc
0.17 Tw
[(Guidelines Network (SIGN) recommendations. Emer)18(g Med J.)]TJ
T*
0 Tw
(2005;22(12):850-4.)Tj
-3.05882 -1.05882 TD
0.02 Tc
0.573 Tw
[(7)20(.)-1112(Hutchinson PJ. Microdialysis in traumatic brain injury--)]TJ
3.05882 -1.05882 TD
0.014 Tc
0.361 Tw
[(methodology and pathophysiology)65(. )55(Acta Neurochir Suppl.)]TJ
T*
0 Tc
0 Tw
(2005;95:441-5.)Tj
-3.05882 -1.05883 TD
-0.034 Tw
[(8.)-1132(Meier U, Lemcke J, Reyer )17(T)75(, Grawe )54(A. Decompressive craniectomy)]TJ
3.05882 -1.05882 TD
0.002 Tc
0.373 Tw
(for severe head injury in patients with major extracranial)Tj
T*
0 Tc
0.025 Tw
[(injuries. )55(Acta Neurochir Suppl. 2006;96:373-6.)]TJ
-3.05882 -1.05882 TD
0.035 Tw
[(9.)-1132(W)40(inter CD, )54(Adamides )55(A, Rosenfeld JV)129(. )18(The role of decompressive)]TJ
3.05882 -1.05882 TD
0.251 Tw
(craniectomy in the management of traumatic brain injury: a)Tj
T*
0.025 Tw
[(critical review)65(. J Clin Neurosci. 2005;12(6):619-23.)]TJ
-3.05882 -1.05882 TD
0.08 Tw
[(10.)-632(Roberts I, )36(Y)100(ates D, Sandercock P)111(, Farrell B, )18(W)80(asserber)18(g J, Lomas)]TJ
3.05882 -1.05882 TD
0.013 Tw
[(G, et al. Ef)18(fect of intravenous corticosteroids on death within 14)]TJ
T*
0.292 Tw
(days in 10008 adults with clinically significant head injury)Tj
T*
0.012 Tc
0.363 Tw
((MRC CRASH trial): randomised placebo-controlled trial.)Tj
T*
0 Tc
0.025 Tw
(Lancet. 2004;364(9442):1321-8.)Tj
28.60424 37.60986 TD
0.287 Tw
[(1)37(1.)-669(Thomas SH, Orf J, )17(W)80(edel SK, Conn )55(AK. Hyperventilation in)]TJ
3.05882 -1.05882 TD
-0.018 Tw
(traumatic brain injury patients: inconsistency between consensus)Tj
T*
0.232 Tw
[(guidelines and clinical practice. J )18(T)35(rauma. 2002;52(1):47-52;)]TJ
T*
0.025 Tw
(discussion 52-3.)Tj
-3.05882 -1.05882 TD
-0.008 Tw
[(12.)-632(Muizelaar JP)110(, Marmarou )55(A, )18(W)80(ard JD, Kontos HA, Choi SC, Becker)]TJ
3.05882 -1.05882 TD
-0.0002 Tc
(D)Tj
0.72183 -0.00001 TD
0 Tc
0.322 Tw
[(P)111(, et al. )55(Adverse ef)17(fects of prolonged hyperventilation in)]TJ
-0.72183 -1.05882 TD
0.136 Tw
(patients with severe head injury: a randomized clinical trial. J)Tj
T*
0.025 Tw
[(Neurosur)18(g. 1991;75(5):731-9.)]TJ
-3.05882 -1.05882 TD
0.016 Tc
0.359 Tw
[(1)16(3)16(.)-616(Battison C, )55(Andrews PJ, Graham C, Petty )17(T)74(. Randomized,)]TJ
3.05882 -1.05882 TD
0 Tc
0.105 Tw
[(controlled trial on the ef)18(fect of a 20% mannitol solution and a)]TJ
T*
0.01 Tc
0.365 Tw
(7.5% saline/6% dextran solution on increased intracranial)Tj
T*
0 Tc
0.061 Tw
[(pressure after brain injury)65(. Crit Care Med. 2005;33(1):196-202;)]TJ
T*
0.025 Tw
(discussion 257-8.)Tj
-3.05882 -1.05882 TD
(1)Tj
0.5 -0.00001 TD
0.164 Tw
[(4.)-632(Marion DW)91(, Penrod LE, Kelsey SF)80(, Obrist )18(WD, Kochanek PM,)]TJ
2.55882 -1.05882 TD
0.262 Tw
[(Palmer )55(AM, et al. )18(T)35(reatment of traumatic brain injury with)]TJ
T*
0.025 Tw
(moderate hypothermia. N Engl J Med. 1997;336(8):540-6.)Tj
-3.05882 -1.05882 TD
0.142 Tw
[(15.)-632(Clifton GL, Miller ER, Choi SC, Levin HS, McCauley S, Smith)]TJ
3.05882 -1.05882 TD
0.106 Tw
[(KR, Jr)55(., et al. Lack of ef)18(fect of induction of hypothermia after)]TJ
T*
0.025 Tw
[(acute brain injury)65(. N Engl J Med. 2001;344(8):556-63.)]TJ
-3.05882 -1.05882 TD
0.1 Tw
[(16.)-632(T)70(emkin NR, Dikmen SS, )17(W)40(ilensky )55(AJ, Keihm J, Chabal S, )18(W)40(inn)]TJ
3.05882 -1.05882 TD
0.264 Tw
[(HR. )55(A)-459(randomized, double-blind study of phenytoin for the)]TJ
T*
0.02 Tc
0.517 Tw
(prevention of post-traumatic seizures. N Engl J Med.)Tj
T*
0 Tc
0 Tw
(1990;323(8):497-502.)Tj
-3.05882 -1.05882 TD
0.298 Tw
[(17.)-632(Perel P)110(, )37(Y)100(anagawa )18(T)74(, Bunn F)80(, Roberts I, )18(W)80(entz R, Pierro )54(A.)]TJ
3.05882 -1.05882 TD
-0.022 Tw
(Nutritional support for head-injured patients. Cochrane Database)Tj
T*
0.025 Tw
[(Syst Rev)65(. 2006;4:CD001530.)]TJ
-3.05882 -1.05882 TD
0.038 Tw
[(18.)-632(van den Ber)17(ghe G, )18(W)80(outers P)111(, )18(W)80(eekers F)79(, )18(V)111(erwaest C, Bruyninckx)]TJ
3.05882 -1.05882 TD
0.098 Tw
[(F)80(, Schetz M, et al. Intensive insulin therapy in the critically ill)]TJ
T*
0.025 Tw
(patients. N Engl J Med. 2001;345(19):1359-67.)Tj
ET
0 0 0 0 k
39.696 726 516 30 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9 0 0 9 39.696 749.8455 Tm
0 0 0 1 k
-0.0001 Tc
(THE)Tj
2.21865 0 Td
0 Tc
0.025 Tw
[(CANADIAN JOURNAL)-238(OF NEUROLOGICAL)-238(SCIENCES)]TJ
-2.21865 -80.04603 TD
(312)Tj
ET
Q
endstream
endobj
49 0 obj
<<
/Filter /FlateDecode
/Length 238
>>
stream
xmK0[n*8rdI&ulvLnu^Z /{bJ/ӻX_q_/pZim>VR+.c,| Dcw#O*T V8Ux]t62[lxBk3j9nj4sgu99<.0Sy-ǠVyC>,^Ǝ=64hNqz8
(r+~mZ
77x
endstream
endobj
50 0 obj
<<
/Type /Annot
/Subtype /Link
/Rect [7.7999997 14.264648 133.62 22.189453]
/Border [0 0 0]
/A 73 0 R
>>
endobj
51 0 obj
<<
/StemH 0
/Descent -204
/Flags 262242
/Type /FontDescriptor
/Ascent 700
/FontFile3 74 0 R
/FontName /EOZUAU+Times-BoldItalic
/FontBBox [-200 -216 992 921]
/StemV 79
/ItalicAngle -11
/XHeight 685
/CapHeight 669
>>
endobj
52 0 obj
<<
/Differences [32 /space 58 /colon 67 /C 77 /M 79 /O
82 /R 97 /a /b /c /d /e /f 104
/h /i /j 108 /l 110 /n /o 115 /s
/t /u /v 142 /eacute]
/BaseEncoding /MacRomanEncoding
/Type /Encoding
>>
endobj
53 0 obj
<<
/StemH 0
/Descent -205
/Flags 98
/Type /FontDescriptor
/Ascent 684
/FontFile3 75 0 R
/FontName /YBJVWL+Times-Italic
/FontBBox [-169 -217 1009 884]
/StemV 23
/ItalicAngle -11
/XHeight 677
/CapHeight 654
>>
endobj
54 0 obj
<<
/Differences [32 /space 44 /comma 46 /period 48 /zero 50 /two
/three /four 55 /seven 58 /colon 65 /A 67 /C
/D 74 /J 77 /M /N /O 82 /R /S
86 /V 90 /Z 97 /a /b /c /d /e
/f /g /h /i 107 /k /l /m /n /o
/p /q /r /s /t /u /v 121 /y 208
/endash]
/BaseEncoding /MacRomanEncoding
/Type /Encoding
>>
endobj
55 0 obj
<<
/StemH 0
/Descent -215
/Flags 34
/Type /FontDescriptor
/Ascent 684
/FontFile3 76 0 R
/FontName /XNBFCG+Times-Roman
/FontBBox [-168 -218 1000 899]
/StemV 84
/ItalicAngle 0
/XHeight 677
/CapHeight 662
>>
endobj
56 0 obj
<<
/Differences [32 /space 37 /percent 40 /parenleft /parenright 43 /plus /comma
/hyphen /period /slash /zero /one /two /three /four /five /six
/seven /eight /nine /colon /semicolon /less /equal 63 /question 65
/A /B /C /D /E /F /G /H /I /J
/K /L /M /N /O /P /Q /R /S /T
/U /V /W 89 /Y /Z 97 /a /b /c
/d /e /f /g /h /i /j /k /l /m
/n /o /p /q /r /s /t /u /v /w
/x /y /z 136 /agrave /acircumflex 142 /eacute /egrave /ecircumflex
149 /idieresis 153 /ocircumflex 168 /registered 208 /endash 212 /quoteleft
/quoteright]
/BaseEncoding /MacRomanEncoding
/Type /Encoding
>>
endobj
57 0 obj
<<
/StemH 0
/Descent -203
/Flags 262178
/Type /FontDescriptor
/Ascent 912
/FontFile3 77 0 R
/FontName /CUULHT+Times-Bold
/FontBBox [-168 -218 998 934]
/StemV 25
/ItalicAngle 0
/XHeight 921
/CapHeight 676
>>
endobj
58 0 obj
<<
/Differences [32 /space 40 /parenleft /parenright 46 /period 49 /one /two
/three /four /five /six 58 /colon 65 /A /B /C
/D /E /F /G /H /I 76 /L /M /N
/O 82 /R /S /T /U 97 /a /b /c
/d /e /f /g 105 /i /j /k /l /m
/n /o /p /q /r /s /t /u /v 120
/x /y 131 /Eacute 142 /eacute /egrave /ecircumflex]
/BaseEncoding /MacRomanEncoding
/Type /Encoding
>>
endobj
59 0 obj
<<
/Type /Font
/Subtype /CIDFontType2
/BaseFont /AAAZZD+NotoSans
/CIDSystemInfo 78 0 R
/FontDescriptor 79 0 R
/W [0 [600]
3 [260]
17 [268 372 572 572 572 572]
25 [572 572]
29 [268]
38 [632]
51 [605]
54 [549]
56 [731]
68 [561 615]
71 [615 564]
74 [615 618 258]
79 [258 935 618 605 615]
85 [413 479 361 618 508]
92 [510]
]
/CIDToGIDMap 80 0 R
>>
endobj
60 0 obj
<<
/Filter /FlateDecode
/Length 322
>>
stream
x]j0E
-Epg胺 [A-YY+8)T`.s4wF(scчd(tsxWmoCcgY2{3L,y6g;';N+}mۛ?0+Xٷnoߨ&L">
endobj
62 0 obj
<<
/Name /Fm1
/BBox [-1.24782 -0.27638 1.16203 2.78828]
/Subtype /Form
/Resources <<
/XObject <<
/Im1 81 0 R
>>
/ProcSet [/PDF /ImageB]
/ExtGState <<
/GS3 63 0 R
>>
>>
/Type /XObject
/Length 35
/Matrix [1 0 0 1 0 0]
/OPI <<
/2.0 <<
/Version 2
/Size [1911 1949]
/CropRect [39.692 27.487 1870.05603 1925.00598]
/Inks [/monochrome (Black) 1]
/Type /OPI
/F (Production-HD:Users:Production:Production Documents:Production Documents: Journal in Progress: 34#3 Aug 2007:figures tables:3128 table 1.tif)
/IncludedImageQuality 1
/Overprint false
>>
>>
/FormType 1
>>
stream
/GS3 gs
q
1 0 0 1 0 0 cm
/Im1 Do
Q
endstream
endobj
63 0 obj
<<
/FL 1
/SM 0.01
/Type /ExtGState
>>
endobj
64 0 obj
<<
/S /URI
/URI (https://doi.org/10.1017/S0317167100006727)
>>
endobj
65 0 obj
<<
/Name /Fm3
/BBox [-0.15681 -3.83959 2.24189 1.6631]
/Subtype /Form
/Resources <<
/XObject <<
/Im2 82 0 R
>>
/ProcSet [/PDF /ImageB]
/ExtGState <<
/GS3 63 0 R
>>
>>
/Type /XObject
/Length 35
/Matrix [1 0 0 1 0 0]
/OPI <<
/2.0 <<
/Version 2
/Size [1876 1060]
/CropRect [38.356 26.585 1784.11902 1028.76501]
/Inks [/monochrome (Black) 1]
/Type /OPI
/F (Production-HD:Users:Production:Production Documents:Production Documents: Journal in Progress: 34#3 Aug 2007:figures tables:3128 table 2.tif)
/IncludedImageQuality 1
/Overprint false
>>
>>
/FormType 1
>>
stream
/GS3 gs
q
1 0 0 1 0 0 cm
/Im2 Do
Q
endstream
endobj
66 0 obj
<<
/Name /Fm5
/BBox [-0.15684 -0.65381 2.24186 6.50966]
/Subtype /Form
/Resources <<
/XObject <<
/Im3 83 0 R
>>
/ProcSet [/PDF /ImageB]
/ExtGState <<
/GS3 63 0 R
>>
>>
/Type /XObject
/Length 35
/Matrix [1 0 0 1 0 0]
/OPI <<
/2.0 <<
/Version 2
/Size [1872 812]
/CropRect [35.314 21.188 1781.078 790.703]
/Inks [/monochrome (Black) 1]
/Type /OPI
/F (Production-HD:Users:Production:Production Documents:Production Documents: Journal in Progress: 34#3 Aug 2007:figures tables:3128 table 3.tif)
/IncludedImageQuality 1
/Overprint false
>>
>>
/FormType 1
>>
stream
/GS3 gs
q
1 0 0 1 0 0 cm
/Im3 Do
Q
endstream
endobj
67 0 obj
<<
/S /URI
/URI (https://doi.org/10.1017/S0317167100006727)
>>
endobj
68 0 obj
<<
/Name /Fm7
/BBox [-0.15695 -5.27532 2.24231 1.87944]
/Subtype /Form
/Resources <<
/XObject <<
/Im4 84 0 R
>>
/ProcSet [/PDF /ImageB]
/ExtGState <<
/GS3 63 0 R
>>
>>
/Type /XObject
/Length 35
/Matrix [1 0 0 1 0 0]
/OPI <<
/2.0 <<
/Version 2
/Size [2072 928]
/CropRect [31.336 36.238 2011.88501 909.98199]
/Inks [/monochrome (Black) 1]
/Type /OPI
/F (Production-HD:Users:Production:Production Documents:Production Documents: Journal in Progress: 34#3 Aug 2007:figures tables:3128 Table 4.tif)
/IncludedImageQuality 1
/Overprint false
>>
>>
/FormType 1
>>
stream
/GS3 gs
q
1 0 0 1 0 0 cm
/Im4 Do
Q
endstream
endobj
69 0 obj
<<
/Name /Fm9
/BBox [-1.24225 -4.54771 1.15668 1.77674]
/Subtype /Form
/Resources <<
/XObject <<
/Im5 85 0 R
>>
/ProcSet [/PDF /ImageB]
/ExtGState <<
/GS3 63 0 R
>>
>>
/Type /XObject
/Length 35
/Matrix [1 0 0 1 0 0]
/OPI <<
/2.0 <<
/Version 2
/Size [1968 988]
/CropRect [35.555 17.778 1908.26294 952.41101]
/Inks [/monochrome (Black) 1]
/Type /OPI
/F (Production-HD:Users:Production:Production Documents:Production Documents: Journal in Progress: 34#3 Aug 2007:figures tables:3128 Table 5.tif)
/IncludedImageQuality 1
/Overprint false
>>
>>
/FormType 1
>>
stream
/GS3 gs
q
1 0 0 1 0 0 cm
/Im5 Do
Q
endstream
endobj
70 0 obj
<<
/Name /Fm11
/BBox [-1.24244 -0.5011 1.1566 5.52179]
/Subtype /Form
/Resources <<
/XObject <<
/Im6 86 0 R
>>
/ProcSet [/PDF /ImageB]
/ExtGState <<
/GS3 63 0 R
>>
>>
/Type /XObject
/Length 35
/Matrix [1 0 0 1 0 0]
/OPI <<
/2.0 <<
/Version 2
/Size [1896 988]
/CropRect [24.272 27.83 1831.18103 958.93298]
/Inks [/monochrome (Black) 1]
/Type /OPI
/F (Production-HD:Users:Production:Production Documents:Production Documents: Journal in Progress: 34#3 Aug 2007:figures tables:3128 Table 6.tif)
/IncludedImageQuality 1
/Overprint false
>>
>>
/FormType 1
>>
stream
/GS3 gs
q
1 0 0 1 0 0 cm
/Im6 Do
Q
endstream
endobj
71 0 obj
<<
/S /URI
/URI (https://doi.org/10.1017/S0317167100006727)
>>
endobj
72 0 obj
<<
/S /URI
/URI (https://doi.org/10.1017/S0317167100006727)
>>
endobj
73 0 obj
<<
/S /URI
/URI (https://doi.org/10.1017/S0317167100006727)
>>
endobj
74 0 obj
<<
/Subtype /Type1C
/Length 2757
/Length1 2757
>>
stream
EOZUAU+Times-BoldItalic C \lt-
8
}002.001Copyright 1994-1997 Stream Technologies Inc. All Rights Reserved.
Turku is a trademark of Stream Technologies Inc.Turku Bold ItalicTurku 0 C K F D U J W . I P E T 3 V M $ O G B Q ),/wx63 5y%
$S Ȉ\C+CJeElay+obx&!*~
sd5Luv+{6vqsf{Q 0bnl61@F^IcezFSb,h~vj/p$|pl{voowum]l/J?{q!Hfmmffmmfb~l##>(ju(AM8v^f2dhLpmxFn`rŻugStsyoCvV@fmmffmmfr/z#qr{Slbv|eqøujWqoxzbvpwB~^Upinqql_~ijbN6.VvW}r=q{r0!M'E''V'R_cjjbcjjb.bjjcbjjc$vnEA\}Vu|Kr̤R|VipTprrb~sv f~T|rcNw -vvbwpO.zn6qh}v.
ݡӯ{a3S8hrɵveSrp}n^GT^4*}5`b'3;5K%09L.nvaBS+iyֿ*Dvp9wkbD/rzFyW4pwzuetwp
/S1BU̹c{pdu߽umZwu{:v1w\ao{}|nv^:VZ?Tn=[mrlrsjYj~qu:|x܋c<\rnA×>3rr}qwU}W}WrQ|V ^U}wIìiO:bFPysjb-v_wwp{V
a&wUgGfFZXn}EI|Bpu}sf_+kjxVs³{\opcwźܷvfUxx|ЙvP3ym1qjw}\q'}WjzbsܼDzuiUqqyy7Ant}yyXbatK\-!4mN